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Tissue engineering combines the principles of medical, life sciences, and 
engineering fields toward the development of biological substitutes to restore, 
maintain, or improve tissue function.  Our laboratory has previously developed 
methods to bioengineer various 3-dimenisonal contractile tissues, including cell-
based cardiac and skeletal constructs.  These methods involve seeding cells on 
a fibrin gel, where cells then proliferate and/or exhibit spontaneous contractility, 
resulting in compaction of the fibrin gel.  During culture the cell front moves 
radially inwards, towards the center of the culture surface and results in the 
formation of bioengineered 3-dimensional tissues.   
Fibrin-based biomaterials are well-suited for bioengineering contractile 
tissues, as it promotes cell growth, wound healing, and tissue regeneration (1-6).  
Fibrin closely replicates extracellular matrix (ECM) components of native muscle 
tissues and its degradation kinetics are compatible with the rate of new tissue 
formation (7).  Therefore all of the bioengineered tissue models described in this 
dissertation were developed using fibrin gel casting strategies (1; 5; 8-10).  









Figure 1.1 Bioengineered smooth muscle tissues. 
A) Ring-shaped bioengineered internal anal sphincter, developed from 
primary rabbit smooth muscle cells.  B) Strip-design of a bioengineered 




It is imperative that bioengineered tissues have a high degree of functional 
testing in order to evaluate tissue-specific function as well as suitability for future 
clinical applications (11).  Functional testing for all bioengineered muscle tissues 
described was evaluated using a custom built force transducer and data 
acquisition software (12; 13).   In addition, cellular characterization of 
bioengineered muscle tissues was also performed.   
Finally, as bioengineered tissue models were developed, there became a 
need for improved methods for culture of bioengineered tissues, to accommodate 
theincreased metabolic demand of the 3-dimensional tissue constructs as 
compared to traditional monolayer culture systems.  The final section of this 
research describes a micro-perfusion system which promotes continuous fluid 





during culture.   In addition, exposure of bioengineered tissues to micro-perfusion 
resulted in some functional improvement of tissues.   
Bioengineered in vitro muscle tissues may provide alternative treatment 
modalities for muscle dysfunction/disease, providing transplantable tissue 
substitutes which can have direct applicability.  In addition to potential clinical 
applications, bioengineered tissues can be used as a 3-dimensional model 
system for basic research and in new drug development as a tool to evaluate 
efficacy and safety. 
 
HYPOTHESIS AND SPECIFIC AIMS 
Congestive heart failure (CHF) is a major medical challenge in developed 
countries.  There are currently 4.8 million patients in the U.S. living with CHF with 
an estimated cost to society of $23.2 billion annually(14).  Heart transplantation 
has been the most successful treatment option to treat severe CHF(15).  
Although the short-term survival rate stands at 81%, widespread applicability of 
heart transplantation is often limited by a chronic shortage of donor organs(16).   
Cardiac tissue engineering may provide a potential solution to the donor heart 
crisis in the future.  Research in the area of cardiovascular tissue engineering is 
focused on the development of functional 3-dimensional cardiac and vascular 
tissue in vitro (6).  Tissue engineered heart muscle could be used clinically to 
patch areas of myocardial infarction while vascular constructs may be utilized as 
bypass grafts, particularly in small diameter applications.  Tissue engineering 




the establishment of cell-cell communication, construction and modification of the 
ECM and angiogenesis (17).  There is an unprecedented need to develop 
models of tissue engineered cardiovascular constructs.   
Our overall working hypothesis is that primary mammalian smooth muscle 
cells derived from gastrointestinal and vascular sources can be cultured in the 
presence of a rapidly degrading fibrin gel to form functional 3-dimensional muscle 
tissue constructs in vitro.  
 
Specific Aim 1 – Determine the optimal cell culture conditions (seeding 
density, viability in culture, and tissue-specific function, with force generation 
as the end variable measured) for the development of 3-dimensional “ring” 
models of anal sphincter and colon tissue, bioengineered in a fibrin matrix 
utilizing primary rabbit smooth muscle cells.    
 
Specific Aim 2 – Determine the optimal cell culture conditions (seeding 
density, viability in culture, and tissue-specific gene expression and 
functionality) for the development of a 3-dimensional in vitro muscle “strip” 
model, bioengineered in a fibrin matrix with primary human aortic VSM cells.  
 
Specific Aim 3 – Design, fabricate, and test a micro-perfusion system to 
support the culture of bioengineered 3-dimensional heart muscle.  The micro-
perfusion system should provide a continuous supply of oxygenated and 




stress conditions observed in vivo.   The goals of the micro-perfusion system 
are to: 1) increase functionality (force generation, gene expression, viability, 
total protein) of bioengineered tissues, and 2) replace the use of a standard 
cell culture incubator.   
 
COMMONALITY THROUGH THESIS RESEARCH 
 There are several re-occurring themes in this body of work.  Firstly, and 
most important, the research described in this thesis describes novel 
bioengineered models for smooth muscle cells and technology to support the 
culture of 3-dimensional construct utilizing custom-build perfusion apparatus.  
Collectively, this body of work adds knowledge base to two critical areas of tissue 
engineering research; development of functional bioengineered models and 
ancillary technology to support these models.  The field of tissue engineering is 
fairly new with incremental additions to its knowledge base.  Typically, exploratory 
research is the norm to establish emerging trends; dominant designs have not 
been developed within the field.  Therefore, the current body of work is aligned to 
the general trends within the field of functional cardio-vascular tissue engineering.   
 Another common theme throughout this body of work is the utilization of 
fibrin to support the formation of bioengineered models for gastrointestinal, 
vascular, and cardiac muscle constructs.  Several studies have shown that fibrin 
has specific characteristics which make it suitable as a biomaterial for tissue 
engineering applications.  Firstly, the formation fibrin gel by the polymerization of 




reaction kinetics (18).  The properties of the fibrin gel have shown to support the 
formation of 3-dimensional models of tissue constructs, due to the resemblance 
to ECM components found in normal mammalian muscle tissue (3; 19).  In 
addition, the degradation kinetics of fibrin can easily be controlled by changing 
the properties of the gel and/or cross-linking the fibrin molecule to stabilize the gel 
(20).  This provides an opportunity to modulate the degradation rate of fibrin to 
match the properties of new tissue formation.      
 
 
RELATIONSHIP OF THESIS RESEARCH TO WORK AT THE AHL 
 The overall research objective within the Artificial Heart Laboratory is to 
develop functional models of cardiovascular structures in vitro and to develop 
supporting technology to modulate the phenotype of the resulting tissue 
constructs.  The current body of work is aligned with both of these objectives.  
The first part of this thesis is focused on the development of novel models for 
vascular structures.  The second part of this work is focused on the development 
of a novel bioreactor system to support the culture of bioengineered tissue 
constructs.  Collectively, the work described in this thesis has been designed and 
executed with the overall global objectives of the AHL in mind.   
    





 The research described in this thesis has been designed to address critical 
scientific and technological gaps in the current knowledge base in the field of 
functional tissue engineering.  Specific Aim 1 has been designed to introduce 
researchers in gastrointestinal research to the numerous advantages functional 
3-dimensional tissue constructs have to offer.  The sphincter and colon muscle 
models described in this thesis are the only published bioengineered models of 
gastrointestinal structures developed in vitro.  This gives researchers in the field a 
tremendous advantage over existing systems for basic research.  Specific Aim 2 
has been designed to extend the work descried in the area of strip models for 
vascular tissue.  Published work has shown the utility of supporting the culture of 
vascular smooth muscle cells within a fibrin matrix.  However, this body of work is 
not well aligned with the field of functional tissue engineering, completely ignoring 
the need for testing contractile properties.  In this thesis, the contractile properties 
of bioengineered vascular tissue fabricated utilizing human smooth muscle cells 
have been evaluated.  In Specific Aim 3, a novel micro-perfusion system is 
described to support the culture of bioengineered heart muscle.  In this part of the 
thesis, an often ignored need to develop supporting technology for bioengineered 
constructs has been addressed.   
 Collectively, this body of work described in this thesis has been designed 
and executed with the overall field of functional tissue engineering in mind.  Every 
study is aimed to address a critical knowledge gap, either scientific or 
technological, thereby providing an incremental addition to the field. 




1.6 OUTLINE OF THESIS 
 Chapter 2 and 3 provide a broad overview of the field of cardiac and 
vascular tissue engineering, respectively.  Seminal work is highlighted and critical 
technological challenges which need to be addressed in the field are highlighted.  
Chapter 4 describes ring models of anal sphincter and colon tissue.  Chapter 5 
provides a detailed description of the formation of a strip model for vascular 
tissue.  Chapter 4 and 5 provide detailed methods for the formation of 
bioengineered constructs as well as thorough characterization of the models.  
Chapter 6 describes a novel micro-perfusion system to support the culture of 
bioengineered heart muscle.  Detailed description of the perfusion system is 
provided and data to demonstrate functional improvement in heart muscle 
constructs resulting from micro-perfusion are presented.  Chapter 7 provides a 








Chapter 2   
 
Engineering the Heart Piece by Piece:  
 
State of the Art in Cardiac Tissue Engineering 
 
SUMMARY 
According to the National Transplant Society (2006), more than 7,000 
Americans in need of organs die every year only for lack of lifesaving organs.  
Bioengineering 3-dimensional organs in vitro for subsequent implantation may 
provide a solution to this problem.  The field of tissue engineering in its most 
rudimentary form is focused on the developed of transplantable organ substitutes 
in the laboratory.   
The objective of this chapter is to introduce important technological 
hurdles in the field of cardiac tissue engineering.  This chapter starts with an 
overview of tissue engineering, followed by an introduction to the field of cardio-
vascular tissue engineering, and finally summarizes some of the key advances in 
cardiac tissue engineering; specific topics discussed in this chapter include cell 
sourcing and biomaterials, in vitro models of cardiac muscle, and bioreactors.  
The chapter concludes with thoughts on the utility of tissue engineering models in 
basic research as well as critical technological hurdles that need to be addressed 







OVERVIEW OF TISSUE ENGINEERING 
Tissue engineering is a rapidly evolving field involving collaborative 
expertise from diverse disciplines including engineering, medical, and life 
sciences (21-25).  In its simplest form, the aim of tissue engineering is to promote 
functional regeneration of damaged tissue utilizing cells cultured in vitro within 3-
dimensional scaffolds to repair and/or replace damaged tissue in patients.  
Tissue engineering strategies are focused on four main areas of research: cell 
sourcing, scaffold design, functional tissue development and finally, development 
of viable commercialization models (Figure 2.1).  The identification of a suitable 
cell source remains a formidable challenge, especially for cardiac applications as 
adult derived cardiomyocytes are difficult to obtain and non-proliferative in vitro, 
thereby limiting their applicability.  The main areas of opportunities for cell 
sourcing include human embryonic stem cells, adult derived stem cells and 
autologous cells derived from patients.  The choice of cell source would vary 
significantly depending on the application; autologous derived skeletal muscle 
cells can be utilized for cardiac regeneration, while autologous derived cardiac 
cells may not be the most feasible choice.  Selection of suitable scaffolding 
material depends on the ability of the material simulate properties of the 
extracellular matrix (ECM), promote cell viability and proliferation, possess easily 
controllable degradation kinetics and have a high degree of immune tolerance 




meet many of these requirements, while new and improved biomaterials with 
improved functionality are continuously being developed.  The next stage 
typically requires successful colonization of the scaffold by the cells; the viability 
of the cells during culture within the scaffold, the ability of the cells to maintain 
differentiated phenotype and the ability of the cells to functional interaction with 
the biomaterial become important considerations.  Once cellularization of the 
scaffold has occurred, guided phenotypic maturation of the cells becomes 
important to promote tissue formation which closely resembles the physiological 
make-up of normal mammalian tissue.  It becomes necessary to provide 
mechanical, electrical, and chemical/hormones cues to support the functional 
development of the tissue.  Bioreactors need to be implemented to induce 
electro-mechanical stimulation of the bioengineered tissue, leading to gene 
expression that closely resembles the gene expression of in vivo tissue.  The 
development of micro-perfusion systems becomes increasing important to 
replicate the physiological flow conditions observed in vivo.  As tissue growth and 
maturation occurs, vascularization and/or functional innervation of the 
bioengineered tissue construct become important.   
The task of engineering functional 3-dimensional constructs is often 
confounded by the degree of characterization required to evaluate the 
physiological performance of the construct.  Functional tests often require in vitro 
assessment of mechanical (force, pressure, compression) and 
histological/biological (gene/protein expression and distribution) properties.  The 




immune acceptance/tolerance.  During the next stage of testing, it becomes 
important to demonstrate the ability of the bioengineered construct to functionally 
integrate with the host tissue to promote the regeneration of damaged tissue 
using suitable animal models.  This is followed by clinical evaluation of the 
bioengineered constructs to demonstrate the ability to translate the research to 
the clinical setting.  The bioengineered constructs are then evaluated by 
guidelines established by regulatory process, such as the Food and Drug 
Administration (FDA), which serve to evaluate the safety and efficacy of the 
bioengineered constructs.  For definitive success of bioengineered functional 
constructs, they must meet the challenges of commercialization, including 
development of business models backed by strong financial resources.  
 
 
INTEGRATION OF CORE TECHNOLOGIES 
 Development of tissue engineering technologies requires collaborative 
efforts from diverse scientific disciplines.  This model of scientific collaboration is 
fairly well established in many scientific endeavors and the novelty of tissue 
engineering places additional challenges in implementing successful 
collaborations.  Development of core technologies for tissue engineering 
research requires expertise from engineering, medical and life sciences 
disciplines.  Evaluating the phases of research for one particular example, 
development of a functional 3-dimensional cardiac patch, will illustrate the flow of 




Identification of the need for an alternative therapy to treat cases of 
myocardial injury would need to begin within the medical profession.  Although 
there have been several therapeutics options available to treat acute myocardial 
infarction, one can see the advantage of utilizing a functional tissue engineered 
3-dimensional patch.  The first and foremost problem would be identification, 
isolation, purification, characterization of a suitable cell source, typically carried 
out by the cell biologists.  The next step would be the development of bioactive 
biomaterials by the engineering team and would require expertise in biomaterial 
synthesis, characterization and induction of bio-activity thereby allowing 
functional interaction with cells.  The ability of the cells to functional interact with 
the biomaterial and promote the formation of 3-dimensional cardiac muscle 
would depend on many factors; attachment of the cells to the fibers of the 
biomaterials via integrin mediated mechanisms and ability of the cells to maintain 
differentiated phenotype during colonization of the scaffold.  Understanding and 
manipulating cell-material interaction necessitates scientific input from 
engineering as well as the life sciences experts.   
 During the early stages of research, there needs to be an effort directed 
towards the development of small animal models, bioreactor technology to 
simulate physiological parameters and modulate the fluid environment of the 
constructs by developing continuous perfusion systems as well as the utilization 
of an array of biochemical markers.  Every group of experts has to contribute to 
their full potential to head these initiatives.  Later stages of research involve 




control for bioreactors and real time monitoring of material properties and 
biochemical markers.  This again demonstrates the need for true genius by 
scientists from each discipline.    
A true collaborative effort between various disciplines is imperative to the 
success of each phase and it is crucial to promote the exchange of technology 
between each phase, revisiting the problem definition at during every stage of the 
process.  This simple example serves to demonstrate the degree of complex 
interactions and exchange of information required at the very early stages of 
scientific development between scientists from medical, engineering and life 
sciences.  Development of a successful model to accomplish this degree of 
scientific and technological collaboration will be a significant challenge for the 
field of tissue engineering.   
 Tissue engineering has traditionally lacked a model for cohesive research.  
The general tendency has been for the establishment of laboratories by single 
investigators in an academic setting.  This has led to the development of 
excellent technological development in a single area of tissue engineering, 
without emphasis on the functional interaction across disciplines.  Although 
single laboratories claim to collaborate with disciplines outside their area of 
expertise, or even recruit research personnel across these boundaries, we do not 
believe this is adequate for the specific research challenge at hand, nor is it done 
in such a way that it changes and improves the overall culture of the tissue 
engineering research community in terms of promoting increased 




often through the collaborative efforts of professional from academic, government 
and industrial background.  Leadership needs to be jointly established by all 
participating members.  Funding will need to be secured by diverse sources like 
federal agencies, philanthropic donations and support from industry.  Intellectual 
property will need to be managed in a manner that promotes a significant degree 
of openness to allow technology development will protecting ownership of the 
inventors.  In our opinion, this will be the only through successful way to develop 
tissue engineering models.   
 
POTENTIAL CLINICAL APPLICATIONS OF BIOENGINEERED CARDIO-
VASCULAR CONSTRUCTS 
The field of cardiac tissue engineering includes not only heart muscle, but 
also tri-leaflet valves, cell based cardiac pumps/ventricles, and vascular grafts.  
Although the focus of this article is on cardiac muscle, other areas of cardiac 
tissue engineering will be briefly discussed for completion.  Most of these fields 
are at early stages of technological development.  There is an opportunity to 
have a significant impact on the future of treatment modalities for cardio-vascular 
disorders (Figure 2.3).     
The most successful strategy for treatment of end stage congestive heart 
failure has been surgical transplantation.  However, widespread applicability of 
heart transplantation is often limited by a chronic shortage of donor organs(15; 
26; 27).  Cardiac tissue engineering may provide a potential solution to the donor 




particularly advantageous in cases of acute myocardial infarction, where 
integration of bioengineered patches with host myocardium could theoretically 
improve the contractile function of the failing left ventricle (Figure 2.3A) (28-34).      
The current treatment options for vascular substitution require the use of 
the mammary artery or saphenous vein for by-pass grafting.  The major 
disadvantages of this strategy is the need for invasive patient surgery and the 
limited quantity of autologous grafting material available.  Synthetic vascular 
substitutes like Dacron and ePTFE lack the cellular components thereby limiting 
functional performance and have limited utility in small diameter applications.  
Patients often suffer from thrombus formation and intimal hyperplasia.  Tissue 
engineering alternatives could potentially eliminate some of these complications 
and may be particularly suitable for small diameter applications (Figure 2.3B) 
(35-39).  The ability to fabricate hollow tubular structures surrounded by smooth 
muscle cells with a lining of endothelia cells on the luminal surface would 
constitute a viable tissue engineered alternative.   
Heart valve substitution is the only effective treatment for end-stage heart 
valve diseases when repair is not feasible (40). Current options are limited to 
mechanical valves (41) and biological (42) substitutes.  Mechanical heart valves 
often require long term anticoagulation while biological substitutes lack the 
mechanical durability for long term function.  Valve replacement for pediatric 
patients is further limited due to the inability of the prosthetic valve to grow with 
the pediatric patient, necessitating several re-operations during the childhood of 




virtually any size, which would grow with pediatric patients(43).  In addition to the 
many challenges of tissue engineering already discussed, the ability to engineer 
tri-leaflet valves is confounded by a complex 3-dimensional geometry 
necessitating complex mold design (Figure 2.3C) (44-48).   
The ability to engineer cell based cardiac pumps may provide an 
alternative to mechanical Left Ventricular Assist Devices (LVADs)(49).  LVADs 
are used as a bridge to transplantation, transporting oxygenated blood from the 
apex of the heart directly to the aorta, completely bypassing the failing left 
ventricle.  A cell based alternative would be composed of a hollow chamber 
surrounded by contracting cardiac cells with one-way valves for unidirectional 
flow and embedded electronics for feedback control (Figure 2.3D).  Sensors 
would receive electrical input from the SA node, permitting contractions that are 
synchronized with the heart.  The cell based alternatives to mechanical LVADs 
would offer a higher degree of immune tolerance reducing the need for long term 




A critical issue in cardiac tissue engineering is the choice of cells for 
construct development.  An ideal cell source for cardiac tissue engineering 
should possess the following characteristics: 1) proliferative, 2) easy to harvest, 
3) nonimmunogenic, 4) ability to differentiate.  Depending on the specific 




(although not limited to): vascular smooth muscle, skeletal myoblasts, fetal 
cardiomyocytes, mesenchymal stem cells, endothelial progenitors, bone marrow 
cells, umbilical cord cells, fibroblasts, embryonic stem cells.  The composition of 
cells is also an important consideration in cardiac tissue engineering.  Cardiac 
tissue in vivo is complex, being composed of multiple cell types.  Cardiac 
myocytes are the main component of the heart, however a combination of 
endothelial cells, fibroblasts, smooth muscle cells, neural cells, and leukocytes 
make up approximately 70% of the totally cells in the working myocardium (50).  
Non-cardiomyocytes play an important role in normal cardiac development and 
function.  Using a triple-cell-based culture of cardiomyocytes, endothelial cells, 
and embryonic fibroblasts, a 3-dimensional model of vascularized cardiac tissue 
has recently been developed (51).  The presence of endothelial cells led to 
increased cardiomyocyte proliferation, while the presence of embryonic 
fibroblasts decreased endothelial cell death and increased their proliferation; 
thereby demonstrating the importance and complexity of functional interactions 
between the various cell types.  Future development of in vitro cardiac models 
which incorporate multiple cell types should lead to improved graft/transplant 
survival with increased functionality.   
Utilization of adult derived stem cells would provide a cell source that can 
be derived from patients and are therefore autologous.  Potential sources of adult 
stem cells for cardiac tissue engineering include bone marrow, peripheral blood, 
and skeletal muscle.  There have been promising results using adult stem cells, 




zone and improved left ventricular function.  Studies evaluating the feasibility of 
cell transplantation provide a good model to understand the utility of various cell 
types for myocardial regeneration (52-54).  Cell transplantation therapies have 
utilized adult derived stem cells skeletal myoblasts (55-60), bone marrow derived 
cells(61-65), and endothelial progenitor cells (66; 67) or embryonic stem cells(68-
72).     
Autologous skeletal myoblasts show expression of contractile proteins and 
form well-differentiated myotubes in vitro and after transplantation in the heart; 
however the nascent myotubes do not form electrical junctions with host 
myocardium and thus are unlikely to participate in a functional syncytium and 
deliver respective work load. Also, myoblasts do not differentiate towards a more 
cardiomyocyte-like phenotype upon in vitro or in vivo physiological stimulation 
and have not demonstrated fatigue resistance required for cardiac application. In 
addition, the time needed to process and expand autologous myoblast cultures 
would make it difficult to deliver them in a timely fashion to a patient in need.  
Although adult stem cells are a promising option for tissue engineering, at the 
present time, their true potential remains unclear.  An important question that 
remains is whether it is possible to induce transdifferentiation of adult stem cells 
at the necessary efficiency.  Recent research effort is focused on growth factors 
and culture conditions that promote cardiac lineage commitment and genes that 
may be introduced to induce cardiac differentiation (73).  
Although the utilization of human embryonic stem (ES) cells is 




great potential for the use of ES cells in cardiac regeneration.  The motivation for 
the utilization of embryonic stem cells are the unlimited proliferative capacity of 
these cells and ability to differentiate into multiple cells types including all cells 
found in the myocardium.  Various studies have demonstrated that mouse and 
human ES cells can differentiate into functional cardiomyocytes (74-76).  
Genetically engineered ES cells can be cultured to yield large-scale generation of 
viable cardiomyocytes for tissue engineering and/or implantation (77-79), thereby 
demonstrating the feasibility of utilizing ES cells for cardiac tissue engineering 
applications.  Recent studies demonstrating the presence of stem/progenitor 
cells in the heart may provide an alternative cell source for cardiac regeneration 
and repair (80).       
 A significant amount of research is directed towards evaluating the 
feasibility of utilizing different cell types for cardiac regeneration.  Although a 
clear direction has not evolved as yet, several promising options are being 
evaluated.  In concluding this section, it may be valuable to compare cell therapy 
approaches with tissue engineering methods for cardiac regeneration.  The main 
advantage that tissue engineering has to offer is the fabrication of a functional 3-
dimensional tissue construct which may be layered onto the damaged 
myocardium.  This presents the opportunity for functional interaction between the 
transplanted construct and the host thereby permitting functional augmentation 







Biomaterials guide the phenotypic maturation of the cardiac cells during 
tissue formation by promoting functional cell attachment and subsequent 
remodeling to form functional 3-dimensional tissue constructs(81-84).  There are 
several requirements for an ideal biomaterial for cardiac tissue engineering 
applications.  The material should support the attachment, viability and 
proliferation of cardiac cells in culture.  The porosity (pore size and distribution) 
should accommodate the colonization of different cell types found in cardiac 
tissue.  The size, orientation and distribution of biomaterial fibers should mimic 
the properties of the cardiac extracellular matrix.  The degradation kinetics of the 
biomaterial should match the rate of tissue formation by the cardiac cells while 
producing non-toxic degradation products.  The mechanical properties of the 
material (tensile strength, elasticity) need to be comparable to the extracellular 
matrix of the heart.  In addition, for in vivo applications the biomaterial should be 
immune tolerant, functionally integrate with host myocardium and support the 
formation of electro-mechanical coupling as well as construct neovascularization.    
Several biomaterials have been utilized to engineer functional 3-
dimensional cardiac tissue in vitro(85).  Two classes of biomaterials currently 
utilized to engineer functional 3-dimensional cardiac tissues are polymeric 
scaffolds (polyglycolic acid(86-89)) and hydrogels (collagen(90-93), fibrin 
(unpublished data), and alginate(94)).   The main advantage of using polymeric 
scaffolds is the ability to provide stable mechanical support to promote cardiac 




therefore have been preferred for many cardio-vascular tissue engineering 
applications.  Hydrogels, on the other hand provide, have been shown to provide 
an environment that more closely stimulates the extracellular matrix of cardiac 
muscle.  Several medications, including the utilization of cross-linking agents 
have been implemented to improve the mechanical strength of the gels.   
The currently utilized biomaterials have shown to adequately support 
cardiac cell remodeling (95-97).  Bioengineered constructs generated by both 
polymeric scaffolds and hydrogels have shown to exhibit contractile, histological 
and biochemical characteristics similar to normal mammalian cardiac muscle (19; 
98; 99).  However, as new models of cardiac muscle are engineered in the 
laboratory with the desire to functionally match the performance of normal heart 
muscle, a new generation of novel biomaterials would also need to be 
developed.    
There has been an emphasis towards the development of “smart” 
biomaterials that are receptive to changes in the physiological environment and 
are adaptive to changes in the degree of tissue maturation(100-103).  The overall 
goal is to program a feedback loop that changes the properties of the materials 
as changes in the physiology of the cells take place.  Consider a hypothetical 
case in which cardiac cells are seeded into the 3-dimensional architecture of a 
“smart” material.  As tissue remodeling takes place, the cardiac cells generate 
extracellular matrix components, mainly collagen.  The rate of synthesis of 
collagen would depend on several variables; viability of the cardiac fibroblasts, 




synthesis of collagen would change over time depending on the balance of these 
factors.  One goal of a “smart” material would be to “sense” the change in 
collagen production and “program” material degradation to match the rate of 
collagen synthesis.  Conceptually, one unit of collagen production will result in 
one unit of material degradation.   
Although conceptual at this stage, there have been several interesting 
examples of the development of “smart” materials (Figure 2.4).  The ability of 
matrix metalloproteinases (MMPs) to recognize and cleave specific amino acid 
sequences makes it a suitable mechanism for the functionality of smart 
biomaterials(104).  A similar concept has been developed by utilization of 
changes in pH upon cellular endocytosis of biomaterials (105).  The pH within the 
endosome is acidic, which can be utilized to cleave acid sensitive carriers of 
biomaterials thereby promoting the controlled release of bioactive factors.  
Changes in the oxidative state of tissue have also been proposed as a potential 
mechanism for the development of smart materials (106; 107).   
The goal in the development of “smart” materials is to engineer 
biomaterials with specifically targeted cell attachment sites, targets for cleavage 
by changes in the physiological environment all linked to a polymer backbone 
containing internalized growth factors (Figure 2.4).  The objective would be to 
utilize the cell attachment site to deliver the biomaterial to specific targets while 
changes in the physiological state of the cells would promote the release of 




cleavage at specific sites results in controlled release of the bone morphogenetic 
proteins into the local environment.   
 
IN VITRO MODELS OF HEART MUSCLE 
When considering the functional requirements that tissue engineered 
heart muscle needs to satisfy, one must aim to recapitulate the anatomy of 
mammalian cardiac muscle.  Although it may not be feasible to develop a perfect 
replica of mammalian cardiac tissue in vitro, certain key characteristics define 
conditions that would be pre-requisite for the development of tissue models of 
heart muscle.  Identification of a suitable cell source, preferably adult derived 
autologous stem cells with physiological compositions of cardiac myocytes, 
fibroblasts and endothelial cells would be necessary.  One would need novel 
biomaterials with properties that replicate the extracellular matrix of the heart.  
The functional integration of cardiac cells with biomaterials would need to result 
in contractile, histological, biochemical and electro-physical properties 
comparable to mammalian heart muscle.  Immune tolerance and 
neovascularization would also be additional constraints placed on tissue 
engineered cardiac constructs.   
Our discussion on in vitro models of heart muscle is divided into 2 
sections.  In the first section we discuss models published by investigators 
across the globe and in the second part we discuss 3 models that have been 




Carrier and colleagues utilized fibrous meshes made from polyglycolic 
acid (PGA) as a scaffolding material for culturing neonatal cardiac 
myocytes(108).  PGA was processed into fibrous meshes to form disk-shaped 
constructs with a very high degree of porosity and seeded with primary cardiac 
myocytes(109; 110).  These studies were the first to demonstrate the formation 
of functional cardiac muscle utilizing scaffolding based strategies.  Eshcenhagen 
developed a model of cardiac muscle by casting a mixture of neonatal cardiac 
myocytes and collagen into plastic molds(111; 112).  The resulting tissue 
constructs, termed Engineered Heart Tissue (EHT), were capable of generating 
fairly high twitch forces(113).  Eschenhagens model was the first 3-D model of 
cardiac muscle in vitro.  Okano utilized temperature sensitive polymer surfaces 
(TSS) to engineer 2-dimensional sheets of cardiac cells,  which were stacked to 
form 3-dimensional tissue constructs (114-117).  The most attractive feature of 
this model is the utilization of the TSS which eliminates the need for synthetic 
scaffolding materials in the contractile region of the tissue engineering cardiac 
muscle.  Akins utilized a rotating bioreactor system to promote the organization 
of isolated cardiac cells on the surface of microcarrier beads (118).  Li utilized a 
gelatin mesh(119-123) while Leor utilized alginate sponges(124; 125) to support 
cardiac tissue formation.  
Our laboratory has spent the past several years evaluating the feasibility 
of utilizing different platforms to engineer functional 3-dimensional cardiac 
muscle in vitro(1; 126-131).  We have currently developed 3 models of contractile 




primary cardiac cells in the absence of synthetic scaffolding materials (Figure 
2.5A), 2) Bioengineered heart muscle (BEHMs) are formed in the presence of a 
rapidly degrading fibrin gel (Figure 2.5B), and 3) Smart material integrated heart 
muscle (SMIHM) utilizes polymeric scaffolding to support cardiac tissue formation 
(Figure 2.5C).   
Cardioids are formed by the spontaneous delamination of a cohesive 
monolayer of primary cardiac cells (132).  The tissue culture surface utilized for 
cardioid formation is specifically engineered to control surface protein 
concentration.  The surface protein promotes cell attachment during initial stages 
of cultures while initiating delamination during the later stages of culture.  In 
addition, soluble factors introduced via media changes, promotes the cardiac 
cells to generate ECM components during the entire culture period.  The cardiac 
cells and ECM self-organize by controlled guidance of the protein adhesion 
molecules.  The main advantage of this model is the ability to promote self 
organization of a 3-dimenisonal tissue construct without the use of synthetic 
scaffolding material.   
BEHMs are formed by the remodeling of primary cardiac cells in the 
presence of a biodegradable fibrin gel (133).  During BEHM formation, the 
cardiac cells are layered on the surface of the fibrin gel and allowed to remodel, 
promoting the formation of functional 3-dimensional heart muscle.  Cardiac cells 
degrade the fibrin gel and produce ECM components during the initial stages of 
construct formation.  As this process continues, the fibrin gel is gradually 




culture.  The scaffolding material promotes ECM production while providing 
temporary support for the cells.  The most attractive feature of this model is the 
formation of heart muscle in a relatively short time period, within 4-5 days.     
SMIHMs utilize a “smart” material to control the formation of heart muscle 
(134; 135).  The material is considered to be “smart” because it closely 
resembles cardiac ECM in vivo and the material can undergo controlled 
degradation upon formation of viable heart muscle.  Utilizing this technology, we 
have engineered SMIHMs by cellularization of these smart materials using 
primary cardiac cells and shown close resemble to normal heart muscle tissue.  
Our current efforts are focused on controlling the rate of material degradation to 
match the rate of tissue formation.  We are also in the process of programming a 
feedback loop in the material to respond to changes in the rate of collagen 
synthesis.   
  
BIOREACTORS AND MICROPERFUSION 
 Bioreactors are an integral aspect of all tissue engineering research and 
are particularly important in the cardio-vascular field due to the hemodynamic 
requirements of bioengineered constructs.  Several classes of bioreactors have 
been utilized in functional tissue engineering(136).  Bioreactors have been 
utilized during scaffold cellularization to obtain a uniform cell distribution within 
the 3-dimensional architecture of biomaterial.  Bioreactors have also been 
utilized to provide physical stimulation to pre-formed 3-dimensional constructs 




promote maturation of cardiac constructs.  In addition to bioreactors, micro-
perfusion systems play an important role in functional tissue engineering.  The 
role of micro-perfusion systems has been primarily to deliver a continuous supply 
of enriched media to the bioengineered construct during in vitro culture.  The goal 
is to closely replicate the in vivo condition whereby a continuous blood supply 
promotes nutrient exchange as well as removal of waste products.  
Bioreactor/micro-perfusion systems have been described for several cardio-
vascular systems including tissue engineered blood vessels(137-141), 
valves(142-147), and cardiac muscle(148-150).  Although the configuration of 
bioreactor systems have varied, the functional requirements have remained 
similar; to simulate physiological conditions (temperature, pH, oxygen tension, 
glucose levels, radial and circumferential stress) under controlled aseptic 
conditions to promote remodeling of cells and ECM.   
 We have developed a bioreactor system to allow the application of 
coordinated mechanical signals to bioengineered constructs during long term in 
vitro culture.  The bioreactor system was designed and fabricated by Dr. Robert 
Dennis, Associate Professor of Biomedical Engineering at the University of North 
Carolina, Chapel Hill.  We have utilized this system in our laboratory with our 
BEHM model.  Each bioreactor allows up to 11 individual tissue specimens to be 
subjected as a group to the same mechanical stimulation protocol.  The tissue 
culture plates are positioned on a movable platform that is controlled by a 
stepper motor driver circuit.  The stepper controller circuit allows for direct user 




experimental protocol.  The actual mechanical strain protocol is programmed 
directly onto the embedded microcontroller prior to each experiment.  The 
stimulation protocols can be carried out for long periods of time (weeks or 
months) while permitting the culture media to be changed manually, as would 
occur in traditional cell culture using Petri dishes.  The design of the bioreactor is 
suitable for transforming the static engineered muscle culture for dynamic 
mechanical loading studies without physical transfer of the construct.  Using this 
system, we have shown that stretching the BEHMs at a frequency of 1 Hz for 7 
days results in a two-fold increase in specific force.     
We have developed a micro-perfusion system in our laboratory, in 
collaboration with Desmond Radnoti, CEO, Radnoti Glass Inc, to support the 
formation of cardiac muscle (unpublished data).  Our system consists of a 
custom biochamber designed to accommodate 11 tissue culture plates, each 
plate stacked vertically on an independent stage (Figure 2.6).  Each plate 
receives an independent media flow with independent outflow manifolds for 
media aspiration.  The internal environment of the biochamber is carefully 
regulated to maintain temperature and carbon dioxide.  The biochamber is 
surrounded by a water jacket to permit flow of heated fluid for temperature 
control.  Carbon dioxide is directly injected into the biochamber and maintained 
at a pre-defined level by feedback control using a solenoid valve.  Cell culture 
media is maintained at constant temperature using a water-jacketed reservoir 
and is oxygenated prior to entering the biochamber.  Media oxygenation is 




the media through a hollow chamber oxygenator.  The temperature, pH, oxygen 
saturation and carbon dioxide values are measured and recorded in real time at 
multiple points within the system.  The main advantage of our system is that is 
does not require the use of a cell culture incubator, thereby permitting complete 
user control of the cell culture environment.   
   
 
UTILITY OF BIOENGINEERED IN VITRO MODELS FOR BASIC RESEARCH 
As new layers of complexity are continually added to our understanding of 
basic biological processes, interdisciplinary approaches will be increasingly 
necessary for successful research advances.  This is demonstrated by the 
upward tendency of funding agencies to provide substantial support for program 
projects involving many contributors from a variety of labs and the growing 
number of major publications with multiple authors from diverse scientific 
backgrounds. Tissue engineering combines principles of engineering and 
biology, leading to seemingly endless applications.  However, the tremendous 
potential of bioengineered tissues for in vitro basic research applications has only 
recently been recognized.   
Cells interpret cues from their immediate microenvironment and the 
growth and differentiation of many cell types is regulated by the interplay of four 
major signaling sources (Figure 2.7): 1) soluble growth factors, 2) insoluble ECM 
and growth substrates, 3) environmental stress and physical cues, and 4) cell-




researchers will miss biological subtleties by only considering cells grown 2-
dimensionally(152).  On the other hand, 3-dimensional tissue explants are 
complex, being composed of several different cell types that are difficult to 
experimentally manipulate individually.  For these reasons, tissue engineering 
has emerged as a powerful technology where isolated cells can be 
bioengineered into 3-D, homogeneous tissues with characteristics similar to 
those observed in vivo.  In addition, bioengineered tissues can be maintained for 
weeks or months in culture under physiological conditions.   
Incorporation of tissue engineering components with cellular/molecular 
based projects has become a powerful approach for basic research.  For 
example, researchers have used an integrated approach to examine the direct 
effects of microenvironment on stem cell specification(153).  By varying matrix 
elasticity and measuring cell morphology, transcript profiles, marker proteins, and 
the stability of responses, they showed that naïve mesenchymal stem cells 
specify lineage and commit to phenotypes with extreme sensitivity to tissue-level 
elasticity.   
Bioengineered tissues can be more easily manipulated for experiments, 
including transfection of cells with expression vectors to control expression of an 
endogenous protein or to give expression of mutated proteins. The use of 
tetracycline-regulated gene expression in bioengineered skeletal muscle tissues 
has been demonstrated.  Although macroscale animal testing remains the 
primary method used for evaluation of toxicological and pharmacological profiles 




used in the future with the use of in vitro bioengineered models.  Researchers 
have developed a microfluidic device consisting of an array of channels and 3-
dimensional tissues embedded in chambers, which can be used to screen drug 
efficacy and toxicity in multiple tissues simultaneously.  Convergence of new 
technologies may provide feasibility for the development and use of a microscale 
bioengineered animal-on-a-chip.   
Researchers can manipulate their materials to control the biology of the 
cells growing within.  The use of biological feedback mechanisms in growth factor 
delivery has also been explored(154).  For example, a growth factor bound to the 
matrix and released upon cellular demand through cell-mediated localized 
proteolytic cleavage from the matrix, which substantially mimics the mechanism 
by which these factors are released in vivo from stores in the natural ECM by 
invading cells in tissue repair(155; 156).   
The main motivation for the development of bioengineered constructs 
seems to be their in vivo utility.  Although this is likely to be one very significant 
application of the constructs, this realization is may not occur within the short 
time future as cardiac tissue engineering is still in its early stages of 
development.  However, other potential applications of bioengineered constructs 
exist and utility as a tool for basic research is one example.   
 
THOUGHTS FOR THE FUTURE 
 There have been several important technological breakthroughs in the 




current technology, primary isolated cardiac cells can be programmed to form 
functional 3-dimensional constructs in vitro.  Several biomaterials have been 
shown to support heart muscle development in vitro and various cell sources 
have been utilized to study cardiac regeneration in vivo.  However, several 
critical technological hurdles need to be addressed in order for the field of cardiac 
tissue engineering to advance.    
Identification of a suitable cell source for cardiac tissue engineering still 
remains a challenging task.  Contractile cells derived from cardiac origin are 
difficult to source while cells from a skeletal origin have not demonstrated the 
necessary fatigue resistance required for cardiac applications.  Human 
embryonic stem cells are barred by technological advancements demonstrating 
fate programming in addition to the political battles that need to be overcome.  
Adult derived stem cells are yet to prove utility for cardiac applications.  Although 
several approaches show promise, a clearly vision has not been established for 
the identification of a suitable cell source with the potential to be utilized for basic 
several leading to translational and finally clinical applicability.   
There needs to be a new generation of biomaterials, developed 
specifically for cardiac tissue engineering applications.  Although the current 
materials have adequately supported the formation of 3-dimensional cardiac 
tissues in vitro, the mechanical performance and biological properties of these 
bioengineered tissues do not resemble the properties of native mammalian 
cardiac tissue.  Novel biomaterials need be developed to more closely match the 




structural proteins.  In addition, new biomaterials need to be programmed with 
feedback control mechanisms to respond to changes in the local environment.  
As an example of feedback control of biomaterials, generation of extracellular 
matrix by cardiac cells would result in programmed degradation of the material in 
proportion to the rate of synthesis of the extracellular matrix.     
 Development of a new generation of bioreactors and micro-perfusion 
systems presents another technological hurdle for the field of functional cardiac 
tissue engineering.  The current body of literature clearly supports the need to 
utilize bioreactors for the formation of functional tissue engineered constructs.  
Current systems are fairly complex and involve some combination of electro-
mechanical stimulation in the presence of micro-perfusion.  One challenge would 
be to develop the ability to evaluate the changes in the functional performance 
outcome of the tissue construct in real time.  As a simple example of real time 
functional assessment, it would be valuable to monitor the contractile 
performance of 3-dimenisonal cardiac constructs during long term culture.  
Another challenge for bioreactor/micro-perfusion development would be the 
implementation of feedback control.  As an example, as maturation of tissue 
engineered constructs takes place, changes in the cellular environment would 
need to be matched by changes in the rate of micro-perfusion to adequately 
support the increased metabolic demands.   
  In conclusion, although several technological milestones have been 




challenges remain.  Future studies designed to address these issues will help 













Figure 2.1 Pathway for the Formation of Bioengineered Constructs. 
The complex roadmap to bioengineering constructs begins with the identification 
of a suitable cell source; cells can be obtained from donor human tissue, derived 
from an embryonic origin, obtained from animal tissue and/or derived from cell 
lines.  The cells are isolated, expanded and characterized under controlled in 
vitro conditions, manipulated to modulate the expression of specific genes and 
then utilized to colonize pre-fabricated biomaterials.  The bioengineered 
constructs are then subjected to various environmental cues in the form of 
electrical and mechanical stimulation as well as micro-perfusion to promote 
phenotypic maturation of the constructs.  This is followed by induction of 
angiogenesis, in vitro testing of the constructs followed by in vivo testing using 
animal models, clinical testing and development and implementation of 









Figure 2.2 Core Technologies Required for Tissue Engineering. 
Implementation of a successful pathway for the formation of bioengineered 
constructs requires functional integration of technical expertise from several 
scientific disciplines; medicine, engineering and life sciences.  Using an example 
of the development of cardiac patches, the interplay between the various cores 
can easily be illustrated.  Identification of the need for novel treatment modalities, 
such as bioengineered constructs, begins within the medical discipline 
necessitating the identification of multi-disciplinary teams.  During the early 
stages of the research, the engineering core works towards the development of 
novel biomaterials while the life science core works towards cell isolation, 
purification and expansion.  Novel cellularization strategies lead to the formation 
of a premature first generation bioengineered construct.  During the second 
stage of research, small animal models are developed by the medical experts 
while sophisticated biological markers are developed by experts in the life 
sciences.  Engineering folks are generally involved in the design and fabrication 
of novel bioreactors and micro-perfusion systems.  Later stages of research 
necessitate the development of large animal models, real time monitoring of 
functional performance with embedded feedback control and non-invasive 
biological markers for in vivo performance of bioengineered constructs.  This 
model of functional integration of core technologies progresses intimately through 
every phase of technological development resulting in the development of 







Figure 2.3 Functional Cardio-Vascular Tissue Engineering at a Glance. 
(A) Bioengineered Cardiac Muscle – The ability to engineer cardiac muscle by 
functionally integrating primary contractile cells with biomaterials results in the 
formation of tissue engineered cardiac patches.  These cardiac patches can be 
utilized to treat cases of acute myocardial infarction to augment the contractile 
function of the failing left ventricle.  (B) Bioengineered Vascular Grafts – The 
ability to fabricate tubular structures utilizing various scaffolds/hydrogels is 
dictated by the design of suitable molds, which is often fairly trivial.  The walls of 
the tubular graft are cellularized with smooth muscle cells while the lumen is 
cellualarized with endothelial cells resulting in the formation of bioengineered 
vascular grafts.  The utility of these vascular grafts would in cases of coronary 
bypass surgery.  (C)  Bioengineered Tri-leaflet Valves – The complex 3-
dimensional architecture of tri-leaflet valves necessitates complex mold 
prototyping to fabricate tissue engineered equivalent.  Once a prototype is 
fabricated, cellularization with myofibroblasts results in functional heart valves.  
(D) Cell Based Cardiac Pumps – The ability to engineer hollow structures with 
cardiac cells wrapped around the periphery can serve as a cell based devices 
capable of generating intra-mural pressure upon electrical stimulation.  
Embedded detectors on the device coupled to the SA node receive electrical 
impulses which are transmitted to electrical stimulators.  This allows the cell 
based pump to contract in synchrony with the host heart.  Cell based cardiac 
pumps can be utilized to treat cases of chronic heart failure, with mechanical left 








Figure 2.4 Smart Biomaterials for Tissue Engineering. 
In vitro development of smart biomaterials necessitates engineering cell specific 
adhesion sites and cross-linking agents to trap soluble factors within the 3-
dimensional architecture of the biomaterial.  In vivo, the biomaterial is guided to 
specific target receptors on the surface of specific cell types promoting cell-
material interaction.  Matrix metalloprotein (MMP) cleavage at the cross-linking 
site promotes the release of the soluble factors into the local environment.  This 
mechanism ensures the delivery of soluble factors to specifically targeted sites 








Figure 2.5  Tissue Engineering Platforms for Heart Muscle. 
 (A) Self Organization – Primary cardiac myocytes and cardiac fibroblasts are 
co-cultured on the surface of a tissue culture plate that has been coated with 
PDMS, natural mouse laminin and engineered with anchor points at the center.  
During co-culture, the cardiac fibroblasts generate pro-collagen which polymerize 
to form collagen fibers.  The collagen provides structural support during the 
remodeling process.  During the early stages of cell culture, the primary cardiac 
cells form a cohesive monolayer using the laminin as an adhesion protein.  
During later stages of cell culture, the spontaneous contractions of the cardiac 
myocytes promote delamination of the cell monolayer.  The cell monolayer forms 
a 3-dimensional construct at the center of the plate and forms attachment points 
with the anchor points.  These tissue constructs are termed “cardioids”.  The key 
element of this model is that the cells form a 3-dimensional tissue construct in the 
absence of any scaffolding material.  (B) Biodegradable Hydrogel – When 
hydrogels are utilized as a tissue engineering platform, the cells are provided 
with structural components to remodel around.  In our case, we have utilized 
collagen type I as the structural element while fibrin is used as a carrier for 




have been embedded in a fibrin gel.  The cardiac cells utilize the collagen to form 
functional 3-dimensional heart muscle.  During the course of construct formation, 
controlled degradation of the fibrin by the cardiac cells results in the release of 
biofactors in the environment.  These biofactors act on the cardiac cells during 
the remodeling processresulting in significantly increased functional performance 
of the construct.  These constructs have been termed “bioengineered heart 
muscle, BEHM”.  (C) Polymeric Scaffolds – The utilization of polymeric 
scaffolds is to provide a pre-fabricated and pre-defined area to guide remodeling 
of cardiac cells to form 3-dimensional tissue constructs.  The polymeric scaffolds 
often offer superior mechanical properties when compared with hydrogel.  We 
have utilized chitosan in our laboratory and used phase separation methods to 
form porous 3-dimenional scaffolds.  Cellularization of the scaffold using cardiac 
cells has resulted in the formation of functional heart muscle.  In addition, the 
degradation of the scaffold is easily controlled by the addition of lysozyme.  We 
have developed strategies to match the rate of new tissue formation with the rate 
of scaffold degradation. This has lead to the formation of heart muscle with high 












Figure 2.6 Micro-Perfusion for Heart Muscle. 
The biochamber consists of multiple independent stages to accommodate tissue 
culture plates.  Media delivery and aspiration takes place independently from 
each plate via manifolds that are positioned directly above the tissue culture 
plates.  The internal environment of the biochamber is controlled to regulate 
temperature and CO2 level.  Media is maintained in a water jacketed reservoir to 
maintain temperature and is oxygenated prior to reaching the plates.  The system 
is run on several pumps which are used to deliver media at a specified flow rate, 
aspirate spent media from the plates, promote mixing of the gases inside the 
biochamber to equalize CO2 levels as well as promote uniform distribution of 
moist air.  All variables (temperature, CO2, O2, pH, flow-rate) are monitored in 











Figure 2.7 Tissue Engineering for Basic Research 
Cellular growth/proliferation and differentiation is regulated by the interplay of 
four major signaling sources: 1) soluble growth factors, 2) insoluble ECM and 
growth substrates, 3) environmental stress and physical cues, and 4) cell-cell 
interactions.  Cells grown 2-dimensionally lack the complex mechanical and 
biochemical interplay, which occurs naturally in vivo.  By developing 3-
dimensional bioengineered models in vitro, we can more adequately replicate 
tissues with characteristics similar to those observed in vivo.  The 3-dimensional 
shape of bioengineered tissues allows for increased cell-cell interplay, leading to 










Chapter 3  
  
Vascular Tissue Engineering:  
 
Design Requirements and Technological Challenges   
  
SUMMARY 
The current treatment options for vascular substitution require the use of 
the mammary artery or saphenous vein for by-pass grafting.  The major 
disadvantage of this strategy is the need for invasive patient surgery and the 
limited quantity of autologous grafting material available.  Synthetic vascular 
substitutes like Dacron and ePTFE lack the cellular components, thereby limiting 
functional performance and have limited utility in small diameter applications.  
Tissue engineering alternatives could potentially eliminate some of these 
complications and may be particularly suitable for small diameter applications.  
Tissue engineering strategies are focused on the development of completely 
biological vascular substitutes with cellular components and the overall objective 
is to engineer a vascular graft with anatomically matched cellular and 
extracellular matrix components.  Tissue engineering strategies have focused on 
fabricating vascular conduits utilizing suitable biomaterials followed by 
cellularization with smooth muscle cells followed by the luminal attachment of 




in vascular tissue engineering.  Design requirements to engineer functional 
vascular substitutes are presented.  Critical analyses of the technological hurdles 
which need to be overcome are also presented.   
 
INTRODUCTION 
Tissue Engineering has been defined as the application of principles and 
methods of engineering and life sciences toward the fundamental understanding 
of structure-function relationships in normal and pathological mammalian tissues 
and the development of biological substitutes to restore, maintain, or improve 
tissue functions.  The overall objective of vascular tissue engineering is to 
fabricate functional vascular conduit utilizing a suitable biomaterial followed by 
cellularization with smooth muscle cells and the luminal attachment of endothelial 
cells.  This chapter presents an overview of the current state of the art in vascular 
tissue engineering, with a focus on design requirements and technological 
challenges.    
The first part of this chapter provides an overview of tissue engineering 
and the advantages of 3-dimensional culture systems as compared to traditional 
2-dimensional monolayer cell culture systems.  This is followed by an overview of 
the critical technological challenges in the field of vascular tissue engineering.  
We then provide a brief description of vascular anatomy and patho-physiology. 
The second part of this chapter looks at the design requirements for 
vascular grafts.  We discuss critical requirements revolving around cell sourcing, 




conditioning.  This is followed by a description of current tissue engineering 
models of vascular grafts that have been published in the recent literature.  
Specific sections are devoted to a discussion of cells, biomaterials, cellularization 
strategies, methodology for the formation of bioengineered grafts and a 
description of micro-perfusion systems and the role of peristaltic flow on vascular 
remodeling.   
In the final section, we provide an overview of our experience in vascular 
tissue engineering and provide a discussion of the models that are current under 
development within our group.  We conclude this chapter with some thoughts for 
the future development of the field of vascular tissue engineering.   
  
 
ADVANTAGES OF 3-DIMENSIONAL BIOENGINEERED CULTURE SYSTEMS 
In vivo, tissues consist of cells arrayed within a complex structural and 
functional framework known as the extracellular matrix (ECM).  The diversity 
observed in the morphology and composition of the ECM contributes to the 
properties and function of each cell and tissue type (101).  Cells are also 
controlled by spatiotemporal cues that reside in the local microenvironment, 
which are presented in a 3-D context.  Cells interpret cues from their immediate 
microenvironment and the growth and differentiation of many cell types is 
regulated by the interplay of four major signaling sources (Figure 3.1): 1) soluble 
growth factors, 2) insoluble ECM and growth substrates, 3) environmental stress 




cells in vitro, cells must first be removed from their native environment which 
provides a multitude of signals that promote their functionality.   Upon isolation 
from their complex in vivo framework, most, if not all, cells types display changes 
in phenotypic, genotype, and functionality.  Although some of these inputs may 
be lost during the cell isolation and expansion process, they can be re-induced if 
the correct culture environment is created.  Therefore a considerable amount of 
research effort has been dedicated to determining the optimal culture conditions 
for the in vitro maintenance of cells.   
 The concept of maintaining live cells separated from their original tissues 
has been around since the 19th century and became a routinely used lab 
technique in the 1950s (157; 158).  More recently, science historians named 
tissue culture one of "medicine's ten greatest discoveries" (159).  The primary 
advantage of tissue culture is of course the ability to maintain cells in a controlled 
environmental under physiological conditions, including temperature and CO2.  
Although traditional cell culture techniques are an immensely important and 
widely accepted method use to maintain cells in vitro, this system also has 
several limitations.   
  Cell isolation can be accomplished using various methods that depend 
on the cell type of interest.    For example, cell isolation could include enzymatic 
and mechanical dispersal of the tissue (1; 132; 160; 161).  Cells need to be kept 
viable while they are separated from their complex framework. The ECM not only 
acts as a scaffold, but also provides a multitude of signals that contribute to the 




population of cells that must be characterized.  Most cells derived from solid 
tissues require an adherent surface for in vitro maintenance.  For standard cell 
culture, cells are placed in a 2-D culture plate with the appropriate soluble 
supplements and maintained in an incubator, which provides the appropriate 
temperature and gas mixture (typically 37º and 5% CO2).  One of the first 
changes a cell undergoes is a loss of the phenotypic characteristics that are 
observed in the tissue from which the cells had been isolated.  Cells grown 2-
dimensionally display altered morphology, most notably as a flattened and more 
spread out appearance, which is likely to distort findings by forcing cells to adjust 
and adhere to flat and rigid surfaces (162; 163).  Attachment and spreading of 
the cells onto the culture surface and is often a prerequisite for cell proliferation.  
In general, cultured cells become more mobile and proliferative in culture, and 
some cells proliferate in vitro that would not normally do so in vivo (ex: 
differentiated cells).  Cells may be sparsely distributed in the culture dish or 
grown in a monolayer, which limits cell-cell and cell-matrix contacts.   
Differentiation characteristics are often lost, making it difficult to relate the 
functionality of cultured cells to the tissue from which they were derived.  The 2-
dimensional environment promotes cell spreading, migration, and proliferation, 
rather than differentiation, which inevitably leads to compromised functionality of 
the cells.  Thus, it is not surprising that multiple studies have shown that cells 
grown in a 2-dimensional environment display altered gene expression patterns 




For effective in vitro testing, it is important that any measurement obtained 
from in vitro experiments can be interpreted in terms of the in vivo response, or at 
least with an understanding of the differences/limitations between the in vitro and 
in vivo systems.  The nature of the response must be carefully considered.  For 
example, toxicity could be measured in vitro via cell survival or metabolism 
assays, although the nature of the in vivo response could be at the tissue level, 
such as an inflammatory reaction.  It has been long known that cell-specific 
functions are better retained when their 3D architecture is kept in tact, therefore 
3-D culture systems have been developed in order to investigate tissue-level 
responses.  Organ/tissue cultures are an alternative method, which can be used 
to maintain the 3-D architecture of cells in vitro.  However organ cultures can not 
be propagated in vitro, and must instead be prepared de novo.  Organ/tissue 
explants are complex, being composed of several different cell types that are 
difficult to experimentally manipulate individually.  Also, to prevent rapid 
deterioration, organ/tissue explants are often placed in a cold (usually 4° C) bath 
that does not replicate normal physiological conditions.  Finally, organ/tissue 
cultures generally have limited viability, sometimes only remaining viable for 
hours after their in vivo removal, and therefore long-term studies are not feasible 
(166).   
The development of 3-D bioengineered tissue models is sometimes 
accomplished by culturing cells in matrices, which allows for a more accurate 
mimic of the in vivo architecture, compared to 2-D culture systems(81).  For 




interactions, compared to cells grown 2-dimensionally.  3-D bioengineered 
tissues can be maintained under physiological conditions and can remain viable 
for several months in culture(1; 126; 127; 129; 167-171).  Bioengineered tissue 
can also be more easily manipulated for experiments by, for example, 
transfecting cells with expression vectors to control expression of an endogenous 
protein or to give expression of mutated proteins. For all of these reasons, tissue 
engineering has emerged as a powerful technology where isolated cells can be 
bioengineered into 3-D, homogeneous tissues with characteristics similar to 
those observed in vivo.   
 
 
OVERVIEW OF VASCULAR TISSUE ENGINEERING 
Tissue engineering strategies are focused on the development of 
completely biological vascular substitutes with cellular components(172-196).  
The overall objective is to engineer a vascular graft with anatomically matched 
cellular and extracellular matrix components and mechanical properties such as 
structural stiffness and strength.  The ability to design a vessel with suitable 
mechanical and biological characteristics would be required to provide a clinically 
viable alternative for cases of bypass surgeries.  By definition, tissue engineering 
is the application of principles and methods of engineering and life sciences 
toward fundamental understanding of structure-functional relationships in normal 
and pathological mammalian tissues and the development of biological 




An overview of certain stages for the formation of vascular grafts is shown 
in Figure 3.2.  In order to replicate the anatomical features of native vessels, 
endothelial cells, smooth muscle cells and myofibroblasts (186; 188; 197) are 
organized in a concentric arrangement in the presence of a suitable 
biomaterial(178; 198).  Several sources are currently being evaluated for the 
vascular cells and numerous biomaterials are being evaluated to support 
vascular graft formation.  Multiple tissue engineering platforms (self organization 
strategies, biodegradable hydrogels, polymeric scaffolds) are being tested to 
promote vessel formation.   
Current models provide an important body of information about the 
organization of vascular cells in 3-dimensional matrices to form functional 
vessels.  Several functional performance metrics (burst pressure, viscoelastic 
properties, histological/biochemical makers) have been utilized to evaluate 
models for vascular grafts.  Several aspects of vascular tissue engineering are 
discussed in detail in the following sections.   
 
 
PATHOPHYSIOLOGY OF VASCULAR DISEASE: ATHEROSCLEROSIS 
 Throughout the 20th century, as medicine rapidly developed and average 
life expectancy got longer, the prevalence of cardiovascular disease increased, 
beginning with 10% at the beginning of the century and rising to 50% of total 
deaths worldwide in developing countries at the start of the 21st century (199).  




the United States have one or more types of cardiovascular disease, including 
one or more of the following: high blood pressure, coronary heart disease 
(myocardial infarction, angina pectoris), heart failure, and stroke (AHA).  It is 
estimated that within the next 15 years, cardiovascular disease will be the cause 
of death for nearly 25 million people worldwide each year, and coronary heart 
disease will prevail over infectious diseases as the number one cause of death 
and disability (199).  
 Understanding the underlying mechanisms of vascular disease first 
requires the basic knowledge of vascular physiology and function.  A normal 
artery is composed of three layers, the tunica intima, tunica media, and adventitia 
(Figure 3.3).  The thin, innermost layer, or the intima, is composed of a 
monolayer of endothelial cells, adjacent to the basal lamina.  Since the 
endothelial cells are in direct contact with the circulating blood, an important 
function of this monolayer is to secrete anticoagulative factors, keeping blood in a 
liquid state.  The inner layer, or tunica media, is a well developed, concentric 
layer of smooth muscle cells, which are intertwined with many layers of 
extracellular matrix rich in elastin.  These smooth muscles are responsible for the 
relaxation/contraction properties of the artery upon chemical stimulation.  The 
outermost layer, or adventitia, contains a small number of fibroblasts and mast 
cells, along with a loose arrangement of collagen fibrils.  This layer also supports 
vasa vasorum (network of small vessels that supply blood to mast cells and 




 The American Heart Association defines atherosclerosis as a “process in 
which deposits of fatty substances, cholesterol, cellular waste products, calcium 
and other substances build up in the inner lining of an artery” (AHA).  There are 
many conventional risk factors that may lead to developing atherosclerosis, 
including smoking, hypertension, hyperlipidemia, diabetes, and obesity.  
Although these risk factors are common, there are individuals who develop 
atherosclerosis as a response to acquired, genetic atherothrombotic events, such 
as abnormal presence of inflammatory markers and abnormal ratios of 
lipoproteins. 
 Studies have shown that atherogenesis most likely begins with an 
atherogenic diet, rich in cholesterol and saturated fat.  These lipoproteins then 
begin to accumulate within the intima of an artery, forming a lesion.  Another 
hallmark of atherogenesis involves recruitment and accumulation of leukocytes.  
As these leukocytes enter and accumulate within the intimal space, they take up 
the modified lipids and begin to turn into foam cells.  This, in turn, stimulates the 
migration of smooth muscle cells into the intima.  There, they divide and produce 
an abundance of extracellular matrix proteins, hardening the fatty streak and 
turning it into a fibrofatty lesion.  A result of these events is a decrease in the 
area of the intima, narrowing the space for blood to flow through, increasing 
blood pressure and ultimately may lead to a myocardial infarction (if lesion is 
within a coronary artery). 
 A common end-stage recovery surgery that is performed on patients 




procedure, a section of another blood vessel, usually acquired from the patient’s 
leg, is used to bypass the occluded artery.  Sometimes, acellularized 
biocompatible blood vessels can also be used to bypass the occlusion.  Efforts to 
develop bioengineered blood vessels, especially ones with small diameters, 
would greatly improve the current bypass procedure.  Primarily, these 
engineered vessels, would most likely contain autologous cells, minimizing an 
immune response.  Secondly, the patient would be able to avoid another invasive 
procedure of explanting a healthy blood vessel from another body part.  It is 
important that current vascular graft research be focused on developing small-
diameter (less than 6 mm) vessels that are biocompatible with patients and also 




DESIGN REQUIREMENTS FOR VASCULAR GRAFTS 
 When considering the design requirements to engineer vascular grafts, it 
is interesting to think about the need to recapitulate anatomical features of native 
vessels versus satisfying the functional needs of the grafts(177; 184).  On the 
surface, it may seem more likely to assume that there is indeed a need to 
engineer a synthetic vascular graft which mimics native vessels in terms of 
cellular and extracellular matrix composition, in additional to all other 
physiological properties.  This is indeed a viable approach, since native vessels 




requirements of vessels without the necessity for anatomical matching.  Based 
on current scientific information, the latter approach has proven more successful 
with Dacron and ePTFE vascular grafts in clinical use without even the presence 
of cells.  On the contrary, a greater proportion of current research is focused on 
re-engineering vascular grafts with anatomical matching.  Our objective in this 
discussion is not to endorse any particular strategy, but rather create awareness 
of parallel thought processes in the field of vascular tissue engineering.   
 When considering the design of an anatomical matched vascular graft, the 
first consideration is cell sourcing, biomaterial development and interaction at the 
cell-material interface (Table 1).  Important scientific requirements include the 
identification of a suitable source of cells (autologous vascular, adipose derived 
or embryonic derived stem cells) the ability to isolate viable cells, cell purification 
and enrichment strategies followed by in vitro expansion and/or differentiation as 
necessary, followed by cellularization and organization to form a functional 
tubular graft while maintaining differentiated phenotype of the cells.  From a 
material standpoint, it becomes important to compare the advantage of utilizing 
commercially available (FDA approved) biomaterials as scaffolds in an attempt to 
expedite technological development verses considerable scientific effort required 
for the development of a new generation of anatomical matched biomaterials.  
Functional remodeling at the cell material interface, both during development in 
vitro and post-implantation become important considerations.  Technological 




200-202) and micro-perfusion systems (203-207) to satisfy metabolic demands 
often limit in vitro development of first generation prototypes.   
 Another important consideration in vascular graft fabrication is 
biocompatibility.  The formation of a continuous endothelial lining is required to 
limit thrombus formation and secrete growth factors to promote the vasoactivity 
of smooth muscle cells.  Utilization of synthetic biodegradable biomaterials 
necessitates non-toxic degradation productions as well as the ability of safe 
removal from of these products from the body.  In addition to being compatibly at 
the biological level, the vascular graft should exhibit mechanical compatibility with 
native vessels and withstand systematic loads without failure.     
An important consideration, often overlooked, is the need to address 
manufacturing, distribution and sales issues during the early stages of 
technological development.  Bulk production versus small scale on site 
manufacturing (greatly increasing cost) would need to be analyzed.  Efficient 
scale –up strategies combined with cryo-perservation, transportation and product 
reconstitution would need to be addressed; current technological advancements 
would need to introduce these concepts at developmental stages of stages of 
development.  Market segmentation, penetration and the ability to compete with 
existing technologies would need to be addressed.  Distribution channels would 
need to be established taking into consideration current trends of direct sales to 
hospitals (where purchasing decisions are made) compared to consumer 





MODELS OF TISSUE ENGINEERED VASCULAR GRAFTS  
There are two categories of bioengineered models being developed for 
vascular tissue engineering models: planar 3-dimensional strip models of 
vascular smooth muscle cells (2; 39; 99; 208) as well as models of tubular 
vascular grafts (209-212).  Both categories of bioengineered models are 
discussed here.    
In addition to the development of vascular conduits, there has been some 
interest in the development of planar 3-D models for vascular tissue engineering 
applications.  There have been many reports of 3-D “tissue equivalents” 
developed in vitro by culturing cells in fibrin matrices(39; 213).  Fibrin-based gels 
have become an effective option for engineering functional muscle tissue, 
providing a matrix that is well suited for the development of contractile tissues .  
Several investigators have demonstrated the capacity to bioengineer primary 
isolated VSM cells into 3-D tissues(99; 214).  VSM cells grown in fibrin show 
increased production of ECM, collagen(215), elastic fibers(216)  , and also exhibit 
mechanical properties that are commensurate with vascular tissue in vivo(217).  
We have used fibrin gel casting to develop a 3-D human VSM strip model in vitro 
(unpublished data).  Bioengineered “VSM strips” result from the spontaneous 
delamination of a confluent monolayer of primary human aortic VSM plated on a 
culture surface treated to control cell adhesion (Figure 3.4). Our bioengineered 
VSM strips are functionally similar to VSM in vivo and remained viable in culture 
for up to 5 weeks.  VSM strips demonstrate spontaneous basal tone and can 




phenylephrine.  Bioengineered VSM strips exhibited calcium-dependent 
contraction and calcium-independent relaxation.   
Three cell types are required for the development of tissue engineered 
vascular grafts: endothelial cells to coat the luminal surface, smooth muscle cells 
to form the medial layer and fibroblasts for the adventitial layer.  Although several 
cell sources are being evaluated for experimental purposes, specific 
requirements would need to be satisfied for clinical applications.  The cells would 
need to be non-immunogenic, functionally active, phenotypically differentiated, 
proliferative, and amiable to cryopreservation for transportation.  Endothelial cells 
derived from vascular specimens(218-222), adipose tissue(223-225) or from 
circulating precursor cells(226; 227) have been evaluated as a potential source 
for vascular tissue engineering application.   
Several biomaterials have been evaluated for use in vascular tissue 
engineering.  Any materials would need to support the culture of smooth muscle 
cells and the formation of an endothelial cell layer on the luminal pressure.  
However, equally important would be the mechanical properties and the ability to 
withstand arterial pressure in excess of 2000 mmHg. Several biomaterials have 
been utilized to engineer vascular grafts and have included de-celluarized 
conduits(228), biodegradable hydrogels like collagen(229) and fibrin(39; 230) 
and polymeric scaffolds like poly-glycolic acid(231) and chitosan (232) (Figure 
3.5).       
There have been several models of vascular grafts reported in the 




conduit utilizing a suitable biomaterial followed by cellularization with smooth 
muscle cells followed by the luminal attachment of endothelial cells.  Different 
cellularization approaches have been utilized: direct layering of cell sheets 
around the peripheral surface or embedding the cells at the time of graft 
formation (Figure 3.6).    
One of the first models of vascular grafts was reported by Eugene Bell and 
colleagues and is regarded as a seminal paper in the field of vascular tissue 
engineering(246).  In this model, primary cells were isolated from a bovine 
source and mixed with collagen.  A three layer structure was developed to 
resemble normal vessel anatomy consisting of a medial layer of smooth muscle 
cells, an adventitia layer of fibroblasts and with a lining of endothelial cells on the 
luminal surface of the vascular graft.  The endothelial cells were shown to be 
functional active expressing von Willebrand factor, creating a barrier to large 
molecules like albumin and releasing prostacyclin, an inhibitor of platelet 
aggregation.  The burst strength of the vascular graft was reported to be 323 ± 
31 mmHg and was shown to be a function of collagen concentration and culture 
time.   
 Robert Nerem and colleagues utilized collagen, fibrin and a mixture of the 
2 gels in conjunction with primary rat aortic smooth muscle cells to generate 
small diameter vascular grafts(247).  One million cells were utilized per construct 
which were cultured for 6 days prior to mechanical testing.   Gel compaction, 
linear modulus and the ultimate tensile stress were dependant on the gel 




study served as an early demonstration of the feasibility of using different 
hydrogels, alone and in combination to support the formation of vascular grafts.  
The mechanical properties of the grafts were determined by the gel composition.   
 Laura Niklason and colleagues utilized smooth muscle cells derived from 
the medial layer of bovine aortas seeded onto tubular grafts fabricated with 
polyglycolic acid(248).  These constructs were cultured under pulsatile flow using 
custom designed bioreactors for up to 8 weeks.  Endothelization of the luminal 
surface was achieved by injecting bovine aortic endothelial cells on directly in the 
lumen of the graft.  The presence of several histological markers was shown and 
indicated the formation of functional vessels.  A burst pressure of over 2000 
mmHg was reported.  This study was valuable in showing the effect of pulsatile 
flow on the formation and maturation of vascular grafts.     
 L’Heureux and colleagues developed a multiple layered model of small 
diameter vascular grafts(249).  Human umbilical vein endothelial cells and 
vascular smooth muscle cells were obtained from healthy newborns donors and 
fibroblasts were obtained from skin specimens from normal adult during breast 
surgery.  Smooth muscle cells and fibroblasts were cultured independently for 30 
days under conditions to promote the formation of extracellular matrix and 
subsequently a cohesive cell monolayer.  A sequential approach was utilized for 
the formation of tissue engineering blood vessels (TEBVs) which consisted of 
physically wrapping the smooth muscle cell sheet around a tubular support 
structure.  This was followed by physical wrapping of the fibroblast cell 




The entire process for the formation of TEBV required a time period of 3 months 
with 3 weeks for the formation of smooth muscle cell sheets, 1 week for media 
maturation, 7 weeks for adventitial maturation and 1 week for endothelization.  
Histological data showed the presence of several vascular specific proteins and a 
burst pressure of over 2000 mmHg was reported.   
 
 
MICRO-PERFUSION SYSTEMS  
 The development of 3-dimensional tissue constructs increases the 
metabolic requirements thereby necessitating the development of micro-
perfusion systems for the continuous delivery of cell culture media and/or 
application of controlled fluid shear to guide functional remodeling.  Micro-
perfusion systems are more universally accepted as systems capable of 
delivering continuous fluid flow to 3-dimensional tissue constructs to support 
metabolic activity of the tissue constructs as well as deliver controlled fluid stress 
to promote functional remodeling of cells and extracellular matrices(250-253).  
Several studies have shown that oxygen can only diffuse through 200 µm of a 
tissue engineered construct, often with a thickness in excess of 200 µm (254). 
Thus, bioengineered tissues may require continuous media perfusion to more 
actively supply oxygen and soluble factors.  The design of normal mammalian 
tissue has incorporated this rate limiting step by extensive vascularization 
(255)and in the case of highly metabolic tissues like cardiac muscle, every 




Vascularization of tissue engineered constructs is a parallel strategy being 
evaluated to support the metabolic requirements of 3D constructs(257).  Several 
approaches for construct vascularization have been evaluated including 
implantation in close proximity to an in vivo vascular pedicle(258), in vitro culture 
in the presence of endothelial cells(259), utilization of angiogeneic factors (260; 
261)(vascular endothelial growth factor, fibroblasts growth factor) and use of 
solid free form fabrication for the development of micro channels in vitro(262; 
263) have all shown promising results.  Although not the focus of this article, 
conceivably, 3D constructs engineered in vitro can be vascularized and then 
supported by a micro-perfusion system.    
 The critical technological challenges in designing micro-perfusion systems 
are the development of micro-chambers for the culture of 3D constructs, the 
ability to control the temperature, pH, oxygen saturation, relative humidity and 
fluid flow rate and monitor/record the changes in functional outcome of tissue 
constructs during long term in vitro culture.  In addition, the entire system needs 
to be maintained under sterile conditions with feedback control to change the 
flow variables to accommodate changes in construct phenotype (Figure 3.7).  
Additional functionality may include continuous measurement and control of 
glucose and lactate.    
 Several systems have been developed to support the long term culture of 
vascular grafts in the presence of peristaltic flow conditions(192; 264; 265).  It 
has been demonstrated that subjecting vascular grafts to peristaltic flow 




extracellular matrix components and increase in the mechanical properties of the 
graft, as measured by the burst pressure(266).   
 
 
VASCULAR TISSUE ENGINEERING AT THE ARTIFICIAL HEART 
LABORATARY 
Our research in the area of vascular tissue engineering comprises three 
main categories; comparing different platforms for the fabrication of tubular 
grafts, evaluating the effectiveness of varying cellularization strategies and 
finally, developing system to mechanical condition the vascular grafts to promote 
functional remodeling.   
Our efforts on fabricating vascular grafts prototypes are focused on 
comparing multiple platforms to support the formation of tubular structures; 
biodegradable hydrogels (fibrin, collagen), acellularized matrices and polymeric 
scaffolds.  Biodegradable hydrogels provide an excellent substrate for cell 
differentiation while cross-linking of fibers results in excellent mechanical 
properties.  Our preliminary work supports the utility of fibrin and collagen to 
promote the vascular graft formation.  Acellularized matrices have the advantage 
of a pre-formed, often optimized extracellular matrix to promote remodeling of 
vascular cells.  Simple detergent based acellularization methods can be utilized 
to completely remove all cellular components without changing the composition 
and properties of the extracellular matrix components; thereby providing an 




strategy utilizes polymeric scaffolds; the ability to control the mechanical 
properties, engineer bioactivity and match the rate of scaffold degradation to 
tissue formation provide ample opportunity to engineer functional vascular grafts.          
We have multiple strategies for cellularization of vascular grafts.  In one 
approach, 3-dimensional patches are fabricated using vascular smooth cells, and 
maintained in culture to promote functional remodeling.  These patches are then 
physically attached on the outer surface of pre-formed tubular structures while 
endothelial cells are injected on the luminal surface.  This cellularization strategy 
is particular useful when utilizing polymeric scaffolds and acellular matrices.  
Utilization of biodegradable gels provides a unique opportunity to embed the 
smooth muscle cells within the 3-dimensional lattice during gel formation.  This 
allows functional interaction at the cell-material interface thereby permitting 
functional remodeling.  Endothelial cases can easily be injected on the luminal 
surface.    
The third component of our vascular tissue engineering research is 
focused on the development of bioreactor and micro-perfusion systems to 
support the functional remodeling of vascular grafts.  We have developed a 
perfusion system to support the culture of tissue engineered constructs without 
the need for a cell culture incubator.  Several variables (temperature, pH, oxygen 
saturation, fluid flow rate) can easily be manipulated to study the effect on tissue 
formation.  In addition, we are working on systems to apply cyclical loads to 
promote tissue maturation.  Collectively, this work aims to promote tissue 




THOUGHTS FOR THE FUTURE 
 A significant amount of progress has been made towards the development 
of bioengineered vascular grafts during the last decade.  However, certain critical 
technological challenges remain to be addressed.  The development of an ideal 
biomaterial to support cellular activity while providing mechanical stability in 
response to arterial pressures would be necessary.  Although several 
biomaterials have been evaluated with varying degree of success, an ideal option 
has not been identified.   
 One critical area of technological development would be in the 
development of micro-perfusion systems for vascular tissue engineering 
applications.  Although several systems have been developed, the level of 
sophistication is limited in terms of the degree of control over processing 
variables.  Most of the current systems utilize a traditional cell culture incubator, 
which limited ability to program user defined variables.  The ability to modulate 
processing conditions to match the phenotypic state of the vascular graft would 
be critical in determining long term viability during in vitro culture.  In addition, the 
ability to delivery controlled fluid shear stresses in pre-defined directions would 
be necessary for maturation of the tissue engineered vascular grafts.   
 Functional integration at the cell-material interface and the ability to guide 
the developmental state of the vascular graft, specifically in response to the 
degree of tissue maturation, has not been given significant attention in the recent 
literature.  At tissue engineered vascular grafts are developed, the phenotypic 




culture.  As the phenotypic state of the construct changes, the culture conditions 
would need to accommodate these changes and modulate processing variables, 
eg. glucose content in media.  Therefore, some degree of guided phenotypic 
maturation of tissue engineered vascular grafts would need to be programmed 
into current culture systems.    
 One fundamental change has to occur in the nature in which tissue 
engineering research is conducted.  In addition to creating a greater degree of 
inter-disciplinary interactions, there needs to be a conscious effort to generate a 
high degree of public awareness as well as develop mechanisms to encourage 
public participation in the research.  The potential impact of tissue engineering 
therapies can be profound.  One mechanism to expedite technological 
developments is via cross-pollination of ideas and novel methodologies from a 















• Identification of a suitable cell source and development of novel 
biomaterials to match the anatomy of native vessels.   
• There needs to be functional integration of the implanted vascular graft 
with the host environment at the cellular and material interfaces providing 
continuum of vasculature. 
• The time required for on site engineering of vascular substitutes is critical 
if single stage cellularization is utilized and needs to be reduced to an 
absolute minimum. 
• Development of functional layers of endothelial cells, smooth muscle cells 
and fibroblasts recapitulating normal vascular anatomy.   
Technological Requirements: 
• Development of Bioreactors and Micro-Perfusion systems to deliver 
controlled mechanical conditioning to modulate the functional outcome of 
the vascular graft.   
Mechanical Properties: 
• The mechanical properties of the vessel wall need to exhibit viscoelastic 
behavior to match the mechanical properties of the native vessel.    
• Mechanical strength as measured by burst pressure needs to be in excess 
of 2000 mmHg.  The mechanical strength is fairly important as the 
vascular substitute should be able to withstand long term hemodynamic 
load without failure. 
Biocompatibility: 
• The vascular grafts need to be resistant to thrombos formation. 
• The extent of smooth muscle proliferation leading to neo-intimal 
hyperplasia needs to be limited. 
• The vascular substitute needs to be non-toxic and be resistant to infection. 
• When utilizing biodegradable materials, the degradation products need to 
be non-toxic and safely eliminated by the body. 
Usability: 
• In order to simplify utilization in a clinical setting, the vascular graft needs 
to be readily available, either as an off the shelf option, or engineered on 
site by cellularization utilizing autologous cells.     
• From a surgical perspective, handling and suturing of the vascular 
substitute needs to be optimized to accommodate the requirements of the 
clinical environment. 
Marketing and Distribution: 
• From a manufacturing standpoint, the vascular substitute needs to be 
amiable to large scale production and retain functionality during cyro-
preservation, transportation and re-constitution prior to use. 
• From a market penetration standpoint, there needs to be a feasibly 
distribution network established with a clear advantage over existing 
therapies.   
• The price needs to be economically feasibly. 
• The vascular grafts needs to maintain longevity upon implantation to 
reduce the likelihood of repeat surgery thereby making the overall therapy 





Table 3.1 Design Requirements for Vascular Grafts.  
The functional requirements that need to be taken into consideration during the 
design of a vascular graft are identified.  Scientific and technologies issues as 
well as mechanical properties and biocompatibility are listed.  Other important 
issues are the usability factor for the vascular grafts as well as considerations of 






Figure 3.1 Advantages of 3D Culture in Tissue Engineering 
Cellular growth/proliferation and differentiation is regulated by the interplay of 
four major signaling sources: 1) soluble growth factors, 2) insoluble ECM and 
growth substrates, 3) environmental stress and physical cues, and 4) cell-cell 
interactions.  Cells grown 2-dimensionally lack the complex mechanical and 
biochemical interplay, which occurs naturally in vivo.  By developing 3-
dimensional bioengineered models in vitro, we can more adequately replicate 
tissues with characteristics similar to those observed in vivo.  The 3-dimensional 
shape of bioengineered tissues allows for increased cell-cell interplay, leading to 






Figure 3.2 Elements of Vascular Tissue Engineering 
The ability to fabricate tubular structures utilizing various scaffolds/hydrogels is 
dictated by the design of suitable molds.  The walls of the tubular graft are 
cellularized with smooth muscle cells while the lumen is cellualarized with 
endothelial cells resulting in the formation of bioengineered vascular grafts.  The 
















Figure 3.3 Functional Anatomy of an Artery 
A normal artery is composed of three layers, the tunica intima, tunica media, and 
adventitia.  The thin, innermost layer, or the intima, is composed of a monolayer 
of endothelial cells, adjacent to the basal lamina.  The inner layer, or tunica 
media, is a well developed, concentric layer of smooth muscle cells.  The 
outermost layer, or adventitia, contains a small number of fibroblasts and mast 








Figure 3.4 Methodology for the formation of bioengineered VSM strips 
Tissue culture plates were coated with PDMS and anchor points were 
engineered by pinning silk sutures 12 mm apart in the center of the culture plate 
with four stainless steel pins.   The plate was sterilized and then a thrombin/fibrin 
solution was mixed in the culture plate which led to polymerization.  (A) Layering 
Approach - Following gel polymerization, primary human VSM cells were plated 
on the surface of the fibrin gel.   (B) Embedding Approach – Cells were 
embedded within the fibrin gel at the time of polymerization.  In both cases, cell 
expansion and increased cell-cell contact resulted in delamination of the cell 
monolayer, which was initiated at the periphery of the culture plate and 
progressed towards the center. The delaminating cell monolayer remained 
attached to anchor points that were placed in the culture dish. Bioengineered 
VSM strips were deemed ready for functional testing when the monolayer formed 









Figure 3.5 Materials Utilized for Vascular Tissue Engineering 
Biodegradable hydrogels like fibrin have often been modified via cross-linking to 
improve the mechanical stability for vascular applications.  Polymeric scaffolds, 
like chitosan, have been fabricated via phase separation methods to result in the 
formation of porous vascular grafts.  De-cellularized matrices have been obtained 















Figure 3.6  Cellularization Strategies 
For the layering approach, cell sheets are fabricated with smooth muscle cells 
(SMCs) and physically “wrapped” around the periphery of tubular conduits.  
Using the embedding approach, SMCs are embedded within the material at the 
time of graft formation.  In both cases, endothelial cells are injected on the 












Figure 3.7 Micro-Perfusion System for Vascular Tissue Engineering 
The vascular grafts are housed in a temperature regulated chamber.  Media is 
maintained in a water-jacketed reservoir with oxygen bubblers.  Utilizing 
peristaltic pumps, the media can be delivered to the luminal surface of the 


















Chapter 4  
  
Development of a three-dimensional physiological model of the internal 
 
anal sphincter bioengineered in vitro from isolated smooth muscle cells 
 
ABSTRACT 
Fecal incontinence affects people of all ages and social backgrounds and can 
have devastating psychological and economic consequences.  This disorder is 
largely attributed to decreased mechanical efficiency of the internal anal sphincter 
(IAS), yet little is known about the pathophysiological mechanisms responsible for 
the malfunction of sphincteric smooth muscle at the cellular level. The objective 
of this study was to develop a three-dimensional (3-D) physiological model of the 
IAS bioengineered in vitro from isolated smooth muscle cells. Smooth muscle 
cells isolated from the IAS of rabbits were seeded in culture on top of a loose 
fibrin gel, where they migrated and self-assembled in circumferential alignment. 
As the cells proliferated, the fibrin gel contracted around a 5-mm-diameter 
SYLGARD mold, resulting in a 3-D cylindrical ring of sphincteric tissue. We found 
that 1) the bioengineered IAS rings generated a spontaneous basal tone, 2) 
stimulation with 8-bromo-cAMP (8-Br-cAMP) caused a sustained decrease in the 
basal tone (relaxation) that was calcium-independent, 3) upon stimulation with 




peak contraction at 30 s that was sustained for 4 min, 4) addition of 8-Br-cAMP 
induced rapid relaxation of ACh-induced contraction and force generation of IAS 
rings, and 5) bioengineered sphincter rings show striking functional differences 
when compared with bioengineered rings made from isolated colonic smooth 
muscle cells. This is the first report of a 3-D in vitro model of a gastrointestinal 
smooth muscle IAS. Bioengineered IAS rings demonstrate physiological 
functionality and may be used in the elucidation of the mechanisms causing 




















Fecal incontinence is associated with reduced anal closure pressure and 
mechanical stress for maintaining tissue coaptation and closure of the anal canal, 
resulting in the inability to control the passage of gas or stools (feces) through the 
anus (267). This is largely attributed to decreased mechanical efficiency of the 
internal anal sphincter (268; 269). Epidemiological studies have shown that fecal 
incontinence affects 2–15% of the population (270-272) , including people of all 
ages and social backgrounds, thus making it one of the most common 
gastrointestinal disorders. A diagnosis of fecal incontinence often leads to 
devastating social, psychological, and economic consequences and a 
significantly lower quality of life(272). Despite the prevalence and disturbing 
nature of this condition, little is known about the mechanisms underlying smooth 
muscle sphincter malfunction. Thus there is a need for a model that provides a 
comprehensive understanding of sphincteric smooth muscle physiology.  
From a clinical perspective, understanding sphincter malfunction in regard to 
fecal incontinence has been limited because traditional anal manometric 
measures are not able to localize specific damage or deterioration to individual 
sphincter structures or discern the underlying cellular or tissue processes 
responsible for function loss. Studies have tended to focus on symptomatic 
individuals and on structure or function, but not both (267). Furthermore, without 
a comprehensive understanding of the pathophysiological mechanisms 




corrective strategies and treatment options for people diagnosed with fecal 
incontinence have been limited.  
Tissue culture was developed in the early 1900s as a technique for studying the 
behavior of animal cells in vitro(157; 158).  Advances in technology have allowed 
the use of tissue culture for many areas of study, including intracellular activity, 
intracellular flux, environmental interaction, cell-cell interaction, and genetics 
(273). The capacity to grow different cell types in culture and subsequently test 
the effects of a variety of drugs, hormones, and other interventions on cellular 
function is of the utmost importance. However, when force production is the 
primary tissue-level function, two-dimensional cell culture is an inadequate model 
for most experimental needs. Furthermore, cells that are propagated and tested 
two-dimensionally lack many of the cellular and environmental cues that play a 
role in differentiation and the establishment of normal physiological function. 
Isolation of single cells and cell suspensions has enabled biochemical and 
mechanical measurements at the cellular level and has advanced our level of 
understanding of smooth muscle function (274). Yet cell suspensions also lack 
the potential for cell-cell interactions and cell-matrix interactions provided by 
three-dimensional (3-D) tissues (273) and lack the tissue-level organization and 
system-level function to allow a direct study of the underlying mechanisms of 
clinical importance (170).  
It is well known that physiological functions of tissues are retained when their 3-D 




muscle strips, have been shown to provide researchers with a 3-D tissue that can 
be easily subjected to controlled changes in perfusion, oxygen availability, and 
agonist-induced stimulation (275-277). Despite the obvious advantages of 
tissue/organ explants, many limitations remain. Tissues are composed of several 
different cell types. For example, IAS muscle strips may be comprised of smooth 
muscle but also any combination of mucosal, epithelial, and/or neuronal cells. 
Thus it is difficult to experimentally manipulate or investigate one tissue 
constituent. Explanted tissues do not last indefinitely and are usually only viable 
for up to 4 h after removal, which prevents long-term investigation (166). Because 
the tissues must be manipulated for experimental purposes almost immediately 
after dissection, they must be prepared de novo for each experiment. Damage to 
the tissue and/or release of material from damaged erythrocytes occurring during 
dissection also inhibits the ability to produce normal functionality and 
environmental conditions. Last, tissue/organ explants must be placed in a cold 
(usually 4°C) buffer or bath to prevent rapid degradation. For these reasons, 
tissue engineering has emerged as a valuable tool that applies the principles of 
engineering and life sciences toward the development of biological models with 
characteristics similar to those observed in vivo. Specific cell types can be 
isolated and bioengineered to yield a homogenous tissue. Bioengineered tissues 
can be maintained in culture for long periods of time under physiological 
conditions (126; 127; 132; 160). Advances in tissue engineering have been 
clinically applied to restore, maintain, and improve tissue function, resulting in 




There have been many reports of 3-D "tissue equivalents" developed in vitro by 
culturing cells in special matrixes or under conditions to promote self-organization 
(99; 126; 127; 170). Fibrin-based gels have become an effective option for 
engineering functional striated muscle tissue, providing a matrix that is well suited 
for the development of contractile tissues (279). Fibrin gels are formed by the 
enzymatic cleavage of fibrinogen by the serine proteinase thrombin, allowing the 
fibrin monomers to spontaneously interact and form fibrils. Fibrin-based gels have 
advantages over synthetic polymer approaches of tissue-equivalent fabrication, 
specifically immediate cellularity of the construct through cell entrapment in the 
forming gel and subsequent fibril alignment via mechanical constraint of cell-
induced gel compaction (99). Cell-mediated fibrin gel contraction occurs, 
mimicking alignment of muscle tissue in vivo (280). Within a fibrin matrix, cells 
rapidly migrate, proliferate, and digest the fibrin, replacing it with their 
endogenous extracellular matrix (2; 39; 99; 208). Vascular smooth muscle cells 
grown in fibrin have shown increased production of ECM, collagen (39; 208), and 
elastic fibers (19) and also exhibited mechanical properties that are 
commensurate with vascular tissue in vivo  (19; 99). Furthermore, fibrin-based 
engineered tissues can be maintained for weeks in culture (99; 127). The 
prolonged life span of engineered tissues allows temporal investigation of the 
effects of cell-cell interactions, growth factors, mechanical and chemical stimuli, 
gene expression, and kinase action on tissue-level function.  
Here we used fibrin gel casting to develop an in vitro model of the IAS from 




cylindrical structures resembling the IAS portion of the gastrointestinal tract. 
Isolated IAS cells seeded in a fibrin construct self align and form a ring in 5–10 
days. The resulting IAS rings are functionally similar to gastrointestinal smooth 
muscle in vivo for >3 wk, including generation of spontaneous tone and agonist-
induced contraction and relaxation of the basal tone with the appropriate stimuli. 
Stimulation with 10–5 M 8-bromo-cAMP (8-Br-cAMP) resulted in a calcium-
independent relaxation of –16.3 ± 2.0 µN from the basal tone. When stimulated 
with ACh, the IAS rings produced a calcium-dependent maximal force of 15.7 ± 
1.4 µN. ACh-induced stimulation was also concentration dependent, with a 
plateau at 10–6 M. Addition of 8-Br-cAMP induced rapid relaxation of ACh-
induced contracted rings. Last, isolated colonic smooth muscle cells were 
bioengineered into 3-D rings and tested in the same manner as sphincteric rings. 
Bioengineered colon rings exhibited spontaneous phasic contractile behavior 
(amplitude: 18 ± 1.99 µN; frequency: 2.45 ± 0.21 cycles/min). Sphincter rings 
showed marked functional differences from colonic smooth muscle rings, 
including the absence of spontaneous phasic contractile behavior. This is the first 
report of a 3-D cylindrical, in vitro model of the IAS that is functionally similar to 
smooth muscle in vivo. This model provides the opportunity for a novel approach 
to investigate smooth muscle function and dysfunction, including the elucidation 






MATERIALS AND METHODS 
Materials and solutions. Growth media (GM) consisted of DMEM (catalog no. 
12430–054; GIBCO) with 15% FBS, 3% penicillin-streptomycin, and 0.6% L-
glutamine. Differentiation media (DM) consisted of 73% DMEM (catalog no. 
12430–054; GIBCO), 20% Media 199, 7% heat-inactivated horse serum, and 1% 
penicillin-streptomycin. Krebs solution contained (in mM) 119 NaCl, 4.6 KCl, 15 
NaHCO3, 1.5 CaCl2, 1.2 MgCl2, 1.2 NaHCO3, and 11 glucose; 0 Ca2+/2 mM 
EGTA Krebs solution was the same except CaCl2 was not included and 2 mM 
EGTA was added. HEPES buffer (pH 7.4) contained (in mM) 115 NaCl, 5.7 KCl, 
2.0 KH2PO4, 24.6 HEPES, 1.9 CaCl2, 0.6 MgCl2, 5.6 glucose, 0.01% soybean 
trypsin inhibitor, and 0.184 (wt/vol) DMEM; 0 Ca2+/2 mM EGTA HEPES solution 
was the same except CaCl2 was not included and 2 mM EGTA was added.  
Cell isolation. Smooth muscle cells were isolated from the IAS of New Zealand 
White rabbits as described previously  (274; 281). Briefly, the IAS (consisting of 
the most distal 3 mm of the circular muscle layer, ending at the junction of skin 
and mucosa) and the distal colon were removed by sharp dissection. The tissues 
were rapidly cleaned and stripped of connective tissue in ice-cold carbonated 
Krebs solution containing 2% penicillin-streptomycin. Separately, the tissues were 
cut into small pieces and transferred to a 100-mm plate containing 15 ml HEPES 
buffer with 0.1% collagenase type II (Worthington Biochemical) for digestion. The 
plates were placed in an incubator (37°C with 5% CO2) for a 1-h digestion period. 




plates were mechanically dissociated using a 10-ml pipette and incubated for one 
additional hour. After the second digestion period was complete, the cells were 
collected and centrifuged at 800 g for 10 min, and the supernatant was 
discarded. The cells were washed and resuspended three times to ensure 
removal of excess collagenase and then resuspended in HEPES buffer or 0 
Ca2+/2 mM EGTA HEPES buffer.  
ACh-induced stimulation and measurement of contraction in suspension of 
isolated IAS smooth muscle cells. To determine the effect of ACh on contraction 
of isolated sphincteric smooth muscle cells, ACh was added to 0.5 ml suspension 
of isolated smooth muscle cells for 30 s or 4 min, with untreated cells as controls. 
The reaction was stopped, and cells were fixed by the addition of 0.1 ml acrolein 
at a final concentration of 0.1%. Individual cell lengths were measured by 
computerized image micrometry (274; 282). The length of cells in the control state 
or after addition of ACh was obtained by measuring 30–50 cells encountered 
randomly in successive microscopic fields from each of three separate 
experiments. The contractile response is defined as the decrease in the average 
length of the cells counted and is expressed as the percent change from the 
control length.  
Preparation of culture dishes and culture of rings. Culture plates (35 mm) were 
prepared as described previously (126; 170). Briefly, 1.5 ml SYLGARD 
[polydimethylsiloxane (PDMS)] was poured in each plate and allowed to cure for 




be easily pinned in place and provided a surface to which, unless coated, the 
cells could not adhere. A cylindrical SYLGARD mold with an upwardly protruding 
5-mm-diameter disk was placed in the center of the dish to provide a luminal 
space for the engineered sphincter or colon (Figure 4.1A). Adhesion of the mold 
to the SYLGARD-coated culture dish was facilitated by pressing the mold firmly 
against the bottom of the dish with forceps. The culture dish was sterilized with 
70% ethanol for 30 min. Ethanol was then aspirated, and culture dishes were 
exposed to ultraviolet light for 1 h. Each dish received 500 µl GM containing 10 
U/ml thrombin, and the dish was agitated until the bottom of the plate was entirely 
coated. Finally, 200 µl of 20 mg/ml fibrinogen was added to each plate and gently 
swirled. The fibrin polymerized 15 min later, and the plates were ready for cell 
seeding.  Primary cells isolated from rabbit IAS and colon tissues were expanded 
separately in 75-cm2 flasks for 1 wk. The cells were then detached from their 
culture flasks with 1.5 ml trypsin-EDTA, collected, resuspended in GM, and 
counted with a hemocytometer. The cell density was adjusted, and 5 x 104, 7.5 x 
104, or 10 x 104 cells/ml was added to the plates in a final volume of 2 ml. Plates 
were returned to the incubator and removed every 48 h to change the media. 
After plating (5–10 days, depending on the density of the cells), GM was replaced 
with DM to promote the formation of adult cellular connections and smooth 
muscle differentiation (99; 127). The DM was replaced every 2–3 days until the 
ring was fully contracted and ready for testing. IAS and colon rings were fully 
formed in 5–10 days; however, time spent in culture for each construct varied 




for each construct. In parallel, fibrin gel constructs were prepared normally; 
however, cells were not added before the incubation period to characterize the 
mechanical properties of the fibrin gel in the absence of cells.  
Measurement of contractile properties. The protocol for measuring excitability 
and contractility of engineered muscle constructs was adapted from previous 
work (12; 127; 170). The following three variables were directly measured: 
torroidal diameter of the muscle construct, passive baseline force (Pb), and peak 
change in isometric force (P). The following two additional parameters were then 
calculated from the measured variables: cross-sectional area (CSA) was 
calculated from the diameter and specific force (sP) by dividing P by the CSA. 
Briefly, engineered sphincters and colons were separated from their molds 
(Figure 4.1E) using forceps, and the minimum ring diameter was measured using 
a calibrated eyepiece and a 5 or 10x objective lens on an inverted microscope 
(Axiovert 25; Zeiss, Thornwood, NY). The cross section was circular; therefore, 
the CSA was calculated using the measured diameter.  
DM in the plate was replaced with 37°C Krebs solution, and the dish was placed 
on a heated aluminum platform that was maintained at a temperature of 37°C 
until the testing was complete. For contractility measurements, one end of the 
engineered sphincter or colon was anchored by a stainless steel pin (10 mm x 
0.1 mm diameter) to the PDMS substrate, whereas another stainless steel pin 
was bent in the shape of a hook and attached by canning wax to an optical force 




see Refs. (126; 283; 283; 284). We followed standard protocols used for 
measuring spontaneous basal tone of IAS muscle strips as follows: stretching of 
the tissue, followed by a period of equilibrium (between 20 and 60 min), where 
the IAS strips stabilized, resulting in the establishment of a new stable baseline of 
tension (275; 275; 285). Thus the bioengineered IAS and colon rings were 
stretched 50% of their resting length using a three-axis micromanipulator. The 
rings were allowed to sit for 20–30 min to reestablish a stable Pb, which was 
arbitrarily set at zero to allow consistent measurements of P.  
Agonist-induced stimulation of bioengineered rings. All force measurements were 
collected at 100 samples/s for 60 s and recorded using a computer with LabVIEW 
data acquisition software (National Instruments, Austin, TX). A median filter of 
rank 2 was applied to all raw force data before being stored to minimize 
digitization noise without causing a phase delay for rapidly changing forces. 
P was determined by subtracting the Pb from the total force values. Data 
analysis was done using LabVIEW and Microsoft Excel software programs. Each 
measurement was repeated three to eight times, and the mean value was 
recorded.  Contractions were induced in the rings by the addition of 10–10 to 10–6 
M ACh. Maximal contractions were seen 30–60 s after addition of the drug. 
Relaxation response in the rings was induced by the addition of 10–5 M 8-Br-
cAMP. Maximal relaxation was achieved after 4 min; therefore, relaxation 




Preparation for histology. In preparation for light microscopy, engineered IAS 
rings were fixed in 4% paraformaldehyde. The rings were processed and 
embedded in paraffin wax according to standard histological procedures (9). All 
sections were made (5–8 µm thick) using a rotary microtome. Staining of the 
histological sections was performed to view general structure using Harris's 
hematoxylin and eosin.  
Statistics. Tissue engineering data are presented as means ± SE for three to 
eight experiments per data point. Differences in mean values were compared 
within groups (e.g., control vs. ACh treatment), and significant differences were 
determined by ANOVA with the post hoc Tukey-Kramer Honest Significant 
Difference test. The level of significance was set at P < 0.05.  
 
RESULTS 
In designing an innovative model of the IAS, the following parameters were 
considered: three dimensionality, remodeling of in vivo structure, expression of 
fundamental in vivo physiological behaviors, potential for cell-cell and cell-matrix 
interactions, enhanced viability, and maintenance under physiological conditions 
in a controlled environment.  
Contractility of isolated IAS cells. ACh (10–7 M)-induced stimulation of isolated 
smooth muscle cells from the rabbit IAS resulted in a sustained contractile 




compared with control cell length (86.86 ± 5.29 µm, n = 150). ACh (10–7 M) 
induced a peak contraction at 30 s (28.85 ± 3.20% decrease in cell length, n = 
150) and was sustained for 4 min (27.09 ± 4.43% decrease in cell length, n = 
150; Figure 4.2). To determine the calcium dependence of this response, parallel 
experiments were performed in 0 Ca2+/2 mM EGTA HEPES buffer. Control length 
of isolated smooth muscle cells preincubated in 0 Ca2+/2 mM EGTA was 88.68 ± 
6.41 µm (n = 150). As expected, ACh-induced stimulation of isolated smooth 
muscle cells resulted in minimal contractile response in the absence of Ca2+ (0.5 
± 4.47 and 4 ± 3.91% decrease in cell length at 30 s and 4 min, respectively; 
(Figure 4.2). These data are similar to the previously published contractile 
response of isolated IAS smooth muscle cells to bombesin and to exogenous 
protein kinase C (281; 282).  
Bioengineering a 3-D IAS or colon ring. Primary cells isolated from the IAS and 
the circular smooth muscles of the colon were cultured separately in 75-cm2 
flasks. After 1 wk, 50,000 or 100,000 cells were transferred to plates containing a 
loose fibrin gel where they proliferated to confluence. As expected, cells 
proliferated and began to digest the fibrin gel, replacing it with endogenous ECM 
(21–23, 40, 46). Cells migrated and self-assembled along the line of force until 
they formed a parallel array of cells. As cells proliferated, they shrunk the fibrin 
gel, contracting it toward the center of the culture dish around a 5-mm-diameter 
SYLGARD mold (Figure 4.1, B-D). The rate of gel contraction was dependent on 
the number of cells initially plated, since constructs seeded with 100,000 cells 




not shown). Tissues were considered "formed" when a 3-D cylindrical tube of 
sphincteric or colonic tissue contracted around the SYLGARD mold (Figure 
4.1D). All fibrin constructs seeded with IAS or colon cells were fully formed within 
5–10 days after cell seeding. The resulting 3-D IAS and colon rings remained 
stable in culture and were experimentally tested between 9 and 23 days.  Parallel 
constructs of gels made without the addition of cells did not exhibit any 
contraction of the gel, and the gels without cells appeared unchanged after 21 
days in culture. Thus contraction of the cell around the SYLGARD mold is 
mediated by the cells seeded in the construct.  
Histological parameters. Histological analysis of the bioengineered IAS rings 
revealed one uniform cell type surrounded by undigested pieces of the fibrin gel 
matrix (Figure 4.3). The cells had many features of differentiated smooth muscle 
cells (fusiform, nonstriated, and uninucleated with the nucleus in the center of the 
cell), although the volume of the perinuclear space was small compared with cells 
in a normal muscle tissue. This suggests that the cells had not reached full 
maturation. As the gel contracted over a period of days, cells increasingly aligned 
in a parallel array. Histological analysis showed a gradient of cell alignment as 
the gel contracted and formed a bioengineered IAS ring (Figure 4.3). Fully 
contracted rings were composed of 20 concentric cell layers. Ring diameters 
averaged 91.3 ± 13.6 µm and had a range of 46.5–145.4 µm. The average CSA 
was calculated as 7,532.9 ± 2,010.3 µm2 and ranged from 1,697.40 to 16,604.90 
µm2. These measurements were used to determine the specific force of each IAS 




Development and relaxation of the basal tone in bioengineered IAS rings. 
Elongation of an IAS ring by 50% of its length resulted in an elevation of tension 
followed by relaxation that was initially substantial, but gradually subsided over a 
period of 20–30 min as a stable baseline of tension was reached. This stable 
baseline was arbitrarily set at zero.  Upon the addition of 10–5 M 8-Br-cAMP, IAS 
rings demonstrated a sustained relaxation response (reduction of the stable basal 
tone) reaching maximal relaxation 4 min after stimulation and subsequently 
resulting in the reestablishment of a new, stable basal tone. Average P for the 
rings after 4 min of incubation with 10–5 M 8-Br-cAMP was –14.8 ± 2.56 µN 
(Figure 4.4B). Stimulation with 10–5 M 8-Br-cAMP in 0 Ca2+/2 mM EGTA Krebs 
also resulted in a relaxation response (–23 ± 4 µN after 4 min), suggesting that 
relaxation was calcium independent (Figure 4.4).  
ACh-induced contraction of bioengineered IAS rings. Bioengineered IAS rings 
stimulated with 10–6 M ACh exhibited a peak P of 10.34 ± 3.2 µN within 30–60 s 
and was sustained for 4 min (Figure 4.5). Maximal P induced by ACh stimulation 
was 33.7 µN, resulting in a specific force (sP) of 2.8 kN/µm2. Rings in 0 Ca2+/2 
mM EGTA Krebs did not contract when stimulated with ACh (0.9 ± 0.2 µN; Figure 
4.5), demonstrating the calcium dependence of the contractile response. 
Furthermore, force generated by ACh-induced stimulation was concentration 
dependent (Figure 4.6), reaching a plateau at 10–6 M.  
  
ACh-induced contraction of IAS rings and subsequent relaxation with 8-Br-cAMP. 




relaxation induced by 10–5 M 8-Br-cAMP. Addition of 10–5 M 8-Br-cAMP resulted 
in an immediate relaxation of ACh-induced contracted IAS rings (Figure 4.7). 
Addition of 8-Br-cAMP induced rapid relaxation of ACh-induced contraction and 
force generation of IAS rings (–14.3 ± 3.8 µN; Figure 4.7B).  
  
Spontaneous phasic contractile behavior in bioengineered colon rings. ACh-
induced contraction and 8-Br-cAMP-induced relaxation of bioengineered colon 
rings showed a similar response pattern to that seen in bioengineered sphincteric 
rings (data not shown). However, colon rings showed one striking functional 
difference from IAS rings; they exhibited spontaneous phasic contractile behavior 
(Figure 4.8). Without the addition of any external stimuli, 100% of bioengineered 
colon rings demonstrated spontaneous phasic contraction. Spontaneous phasic 
contractions were recorded before, during, and after experimental testing (while 
the ring was still attached to the recording equipment), depending on the 
individual ring. Data were recorded at 1-min intervals continuously until 
contractions stopped. If uninterrupted, spontaneous phasic contractions persisted 
(amplitude: 18 ± 1.99 µN; frequency: 2.45 ± 0.21 cycles/min), on average, for 
10.3 ± 2.19 min. Spontaneous phasic contractions were not seen in any IAS 









Despite the prevalence of fecal incontinence, little is known about the 
mechanisms underlying sphincter malfunction. Previous research attempts to 
understand IAS physiology, including tissue culture, cell suspensions (281; 282; 
286) and tissue explants (275-277; 286), have advanced our knowledge of 
smooth muscle function. However, each technique has its own limitations; thus, 
smooth muscle function is still not clearly understood. New technological 
advances in tissue engineering, cell survival, and the utilization of 3-D matrixes 
offered new opportunities to engineer 3-D IAS sphincters. Tissue engineering 
incorporates three dimensionality resembling tissue explants and a homogenous 
population of cells similar to cell suspensions and utilizes tissue culture 
techniques to provide a controlled environment under physiological conditions in 
which tissues can survive for extended periods of time. More recently, fibrin-
based tissue engineering of arterial smooth muscle has revealed a promising new 
technique for investigating smooth muscle (99). Using fibrin gel casting, we have 
developed a 3-D model of the IAS in vitro from isolated rabbit smooth muscle 
cells. This system uses a homogenous population of isolated sphincteric smooth 
muscle cells and, when seeded on a fibrin gel, they self-organize, forming 3-D 
functional tissues. In this study, all IAS rings formed in 5–10 days. Previous work 
has shown fibrin-based tissue construct viability for up to 40 days (127). Our IAS 
rings were only tested between 9 and 23 days in culture and therefore provide 
evidence for viability beyond 3 wk. Bioengineered IAS rings demonstrate 




independent manner by the addition of 8-Br-cAMP or increased (contraction) in a 
calcium-dependent manner by the addition of ACh. Addition of 8-Br-cAMP also 
induced rapid relaxation of ACh-induced contracted IAS rings (Figure 4.7). These 
data provide evidence of physiological functionality. In addition, the absence of 
spontaneous phasic contractile behavior in IAS rings, which was seen in 100% of 
bioengineered colon rings, demonstrates tissue specificity. This model is highly 
reproducible and will offer an effective method for investigation of smooth muscle 
function because it combines the major advantages of previously reported 
research methods into one technique.  
Bioengineered IAS rings exhibited physiological behavior functionally similar to 
smooth muscle in vitro. Upon seeding, cells began digesting the fibrin matrix, 
replacing it with their own ECM (2; 39; 127). As the cells proliferated, they self-
organized along the line of force, forming a parallel array of cells analogous to 
what is observed in 3-D and mechanically strained cultures(287-289). The rate of 
ring formation was dependent on the number of cells initially plated, although this 
did not appear to affect force generated, since the magnitude of force generated 
by IAS rings was consistent regardless of the seeding number (data not shown). 
This was consistent with previous studies involving fibrin-based muscle 
constructs (127). The cells appeared to proliferate within the fibrin gel only until 
they reached confluence, regardless of seeding density. This suggested that 
normal density-dependent contact inhibition of cell division (290) had occurred 




Agonist-induced stimulation showed that bioengineered rings were functionally 
similar to smooth muscle in vivo. IAS rings demonstrated a stable, spontaneous 
tone until stimulated by an agonist. IAS rings showed sustained calcium-
independent relaxation of the basal tone in response to 10–5 M 8-Br-cAMP. This 
is similar to smooth muscle in vivo, where relaxation is largely mediated by cAMP 
and is calcium independent (280; 291; 292). Upon stimulation with the same 
concentration of ACh, both IAS rings and isolated IAS single cells exhibited a 
peak P within 30–60 s after stimulation that was sustained for 4 min (Figures 4.2 
and 5A). Contraction of both isolated single cells and bioengineered rings were 
calcium dependent (Figures 4.2 and 5A). These similarities suggest that 
bioengineered IAS rings have the sensitivity of isolated single cells, which may be 
because of the lack the barriers present in muscle strips, such as innervating 
nerves, epithelial lining, and serosa, and therefore provide an in vitro opportunity 
to experimentally manipulate one 3-D tissue constituent. ACh-induced contraction 
of both isolated single cells and bioengineered rings also corresponds to 
previously described ACh-induced contraction of human IAS muscle strips (275-
277). Preincubation of engineered IAS rings with 10–6 M ACh did not affect the 
relaxation response induced subsequently with 10–5 M 8-Br-cAMP, since IAS 
rings demonstrated an immediate shift from contraction to relaxation after 8-Br-
cAMP-induced stimulation (Figure 4.7). Bioengineered IAS rings have the ability 
to contract and relax within minutes, similar to the capacity seen in vivo. 
Therefore, 3-D engineered IAS constructs exhibited several physiologically 




The characteristic formation of bioengineered IAS rings from isolated sphincteric 
cells is exclusive to the IAS. Bioengineered colon constructs demonstrated 
spontaneous phasic contraction in the absence of external stimuli. Bioengineered 
colon constructs were made from isolated colonic cells from the same animals 
used to make IAS rings. The frequency of bioengineered colonic phasic 
contractions (2.45 ± 0.21 cycles/min) was similar in frequency to that seen in 
colonic muscle strips (2–4 cycles/min)(293). As expected, bioengineered IAS 
rings did not exhibit the spontaneous phasic contractile behavior at any time. This 
suggests that IAS constructs, prepared using adjacent portions of the 
gastrointestinal tract from the same animals, exhibited physiological functionality 
and characteristic tissue specificity that are unique to the IAS.  
Although the engineered rings described here provide an important model for 
studying sphincteric smooth muscle, it is important to note that these cells were 
not fully mature. Histological analysis of the bioengineered rings revealed a 
homogenous composition of differentiated smooth muscle cells that had not 
reached full maturation. Maturation of smooth muscle cells involves continuous 
regulation by a variety of environmental factors, including hormonal signals and 
neural and mechanical input (294; 295). Although it is known that these factors 
influence the maturation of smooth muscle cells, the specific role of each factor in 
vivo is not clearly understood (295). Optimization experiments for IAS constructs 
could be designed in which each physiological input is altered to maximize cell 
maturation. This would improve the engineered IAS rings but would also 




general. Ross and Tranquillo (99)  revealed increased growth of smooth muscle 
cells in a fibrin matrix (measured by collagen production) associated with GM 
(containing DMEM supplemented with FBS) vs. DM (consisting mainly of media 
199). After formation of the ring, we attempted to promote differentiation by 
replacing the normal GM with a differentiated GM that has fewer mitogenic 
signals, therefore suppressing mitosis. This demonstrates the association 
between maturation and increased force production. Although our IAS rings were 
developmentally arrested and had not reached full maturation, this model is well 
suited for investigation of smooth muscle development, maturation, and 
maintenance of functional smooth muscle.  
Although fibrin gel-based constructs have previously been studied, a quantitative 
comparison of force generation was not possible, as these labs did not have the 
equipment necessary for active force testing of bioengineered tissue constructs. 
Tranquillo and colleagues (2; 99; 208; 296) provide the necessary foundation for 
this area of research, demonstrating and characterizing arterial smooth muscle 
tissue growth and development within a fibrin matrix and the resulting tensile 
properties. However, fibrin-based engineering of smooth muscle has been limited 
to vascular/arterial smooth muscle. Furthermore, there are no data available that 
report the active forces generated by fibrin-based smooth muscle constructs. This 
is the first report of active forces, including specific force, generated by fibrin-
based smooth muscle constructs. Furthermore, this paper provides the first 
illustration of not only gastrointestinal smooth muscle, but sphincteric smooth 




advances fibrin-based engineering of smooth muscle tissue by investigating and 
correlating the functional properties, including measurements of P in response to 
agonist-induced stimulation. Specific force calculated for bioengineered IAS rings 
was 2.8 kN/m2. The only available comparison of force generated by smooth 
muscle was explanted muscle strips from humans (10.2 kN/m2) (275), which is 
3.6-fold more force than the IAS rings. Nerem and Ensley (297) report significant 
variation in the mechanical strength of smooth muscle grown in artificial scaffolds 
among different species. Therefore, the lower force generation induced by ACh in 
these engineered IAS rings could be in part attributed to the different model 
systems being compared (human muscle vs. rabbit muscle). The difference in 
specific force generated in human muscle strips vs. bioengineered IAS rings may 
also be the result of the developmental state of the cells, since our system has 
not yet incorporated all of the environmental cues necessary for smooth muscle 
to reach full maturation. Furthermore, bioengineered rings were made using a 
homogenous smooth muscle population grown in a fibrin matrix. Although it has 
been shown that cells grown in a fibrin matrix rapidly migrate, proliferate, and 
then digest the fibrin, replacing it with their own ECM (2; 39; 99; 208), fibrin itself 
is compliant compared with the rigid ECM seen in vivo and therefore will not 
transmit force as well. Histology revealed that the bioengineered rings were 
composed of cells surrounded by pieces of undigested fibrin matrix. To address 
this issue in future experimentation, growth factors could be added to increase 
ECM production. For example, transforming growth factor (TGF) has previously 




(99). Incorporating TGF- into our system may therefore increase ECM production 
and cell differentiation, resulting in a less compliant ring with enhanced force 
production and transmission. Furthermore, alteration of the method in which the 
cells are seeded may also lead to increased force generation in bioengineered 
constructs, for example, mixing the isolated cells directly with the fibrin before 
polymerization, rather than after, to increase homogeneity of the ring and reduce 
the percentage of undigested fibrin comprising the ring. Future research will be 
required to optimize this system using improved contractility as the outcome 
measure.  
In conclusion, a fibrin-based model of the IAS has been produced. In this model, 
IAS cells self-organize in a 3-D fibrin matrix. The resulting 3-D rings show tissue 
specificity to the IAS, are highly reproducible, and are functionally similar to IAS 
smooth muscle in vivo. Our fibrin-based constructs provide the opportunity to test 
the effects of various pharmacological agents, growth factors, and mechanical 
interventions on smooth muscle function. This is the first report of a functional in 
vitro model of the IAS that may be used in the elucidation of the mechanisms 
causing smooth myogenic sphincter malfunction and the investigation of 









Figure 4.1 Preparation and Functional Testing Set-up 
A: preparation of culture dishes; 35-mm plates were coated with 1.5 ml 
SYLGARD [polydimethylsiloxane (PDMS)] and were cured for 24 h. A 5-mm-
diameter SYLGARD mold was placed in the center of the plate to provide a 
luminal space. The plates were sterilized with 70% ethanol for 30 min and then 
treated with ultraviolet light for 1 h. Growth media (500 _l) containing 10 U/ml 
thrombin was added to each plate, and care was taken to make sure the media 
covered the entire surface. To polymerize the gel, 200 _l of 20 mg/ml fibrinogen 
were added and swirled. After 15 min, the plates were ready for cell seeding, and 
media was added. B-E: formation of 3-dimensional bioengineered internal anal 
sphincter (IAS) constructs. IAS cells fused and contracted the fibrin gel around a 
5-mm SYLGARD mold. Progression of fibrin gel contraction leading to the 
formation of a fully formed engineered sphincteric ring is shown (B-D). After ring 
formation, the engineered sphincter was released from its mold (E) before 
mechanical testing. F and G: mechanical testing of 3-dimensional engineered 
IAS rings. The construct was placed on an aluminum heating plate and prepared 
for mechanical testing (F). G is an enlarged view of F. After release from its mold, 
the IAS ring was secured to the SYLGARD substrate using a stainless steel pin 
(G, right). The other end was attached to a hook-shaped stainless steel pin and 









Figure 4.2 Effect of ACh on isolated IAS rabbit cells in HEPES buffer vs.0 
Calcium/2 mM EGTA HEPES buffer.   
ACh (10_7 M) was added to 0.5 ml of the cell suspension for 30 s or 4 min with 
untreated cells as controls. The reaction was stopped, and cells were fixed by the 
addition of 0.1 ml acrolein at a final concentration of 0.1%. Individual cell lengths 
were measured by computerized image micrometry. The length of cells in the 
control state or after addition of ACh was obtained by measuring 90–100 cells 
encountered randomly in successive microscopic fields from each of 3 separate 
experiments. Contraction was defined as the %decrease in cell length compared 
with control. In HEPES buffer, peak contraction (28.85 _ 3.20%) was seen at 30 
s and was sustained for 4 min (27.09 _ 4.43%). Isolated cells preincubated in 0 
Ca2_/2 mM EGTA HEPES exhibited little contraction at 30 s (0.5 _ 4.47%) and at 











Figure 4.3 Histology of IAS rings. 
Histological cross section of bioengineered IAS ring stained with hematoxylin and 
eosin. Photograph (magnification _400) showing a portion of an engineered IAS 
ring with pieces of undigested fibrin gel (G) and cells that have not yet aligned 














Figure 4.4 Relaxation of the basal tone in IAS constructs. 
A: representative tracing of the effect of 10_5 M 8-bromo-cAMP (8-Br-cAMP) on 
IAS rings in Krebs vs. 0 Ca2_/2 mM EGTA Krebs buffer. Data points represent 5 
successive readings of the decrease in resting force by IAS rings after the 
addition of 8-BrcAMP to the construct in Krebs vs. 0 Ca2_/2 mM EGTA Krebs 
buffer. IAS rings, in both Krebs and 0 Ca2_/2 mM EGTA Krebs buffer, showed a 
maximum and sustained relaxation _3–4 min after the addition of 10_5 M 8-Br-
cAMP. B: IAS rings responded functionally to 8-Br-cAMP in a calcium-
independent manner.  8-Br-cAMP (10_4 M) induced relaxation of the basal tone 










Figure 4.5 Kinetics of IAS rings in response to ACh. 
A: details of the kinetics of bioengineered IAS rings in Krebs vs. 0 Ca2_/2 mM 
EGTA Krebs buffer 1 min after stimulation with 10_6 M ACh. Measurements 
were collected at 100samples/s for 60 s, and graph was generated using 
Microsoft Excel. B: kinetics of ACh-induced (10_6 M) force generation. Data 
points represent 5 successive readings of the force generated by IAS rings after 










Figure 4.6 Dose-response curve for the effect of ACh on bioengineered IAS 
rings. 
Responses are expressed as %maximal contraction, and data points are means 
_ SE of 3–8 experiments. Force generated by ACh-induced stimulation was 
concentration dependent, reaching a plateau at 10_6 M. *Significant difference 








Figure 4.7 Effect of ACh and subsequent addition of 8-Br-cAMP on an IAS 
ring in Krebs buffer. 
A: representative tracing of IAS ring response to 10_6 M ACh and subsequent 
addition of 10_5 M 8-Br-cAMP. Data points represent successive readings of the 
force generated by IAS rings after the addition of ACh followed by addition of 8-
Br-cAMP. Arrows indicate the time at which the drug was added. Bioengineered 
IAS rings responded functionally in response to both ACh and 8-Br-cAMP. 
Addition of 10_5 M 8-Br-cAMP resulted in an immediate relaxation of ACh-
induced contracted IAS rings. B:average relaxation from 10_5 M 8-Br-cAMP after 














Figure 4.8 Spontaneous phasic contractile behavior in bioengineered colon 
rings 
Bioengineered colon rings exhibited spontaneous phasic contractile behavior 
without the addition of any external stimuli. Bioengineered colon rings (100%) 
demonstrated spontaneous phasic contraction (amplitude: 18 _ 1.99 _N; 
frequency: 2.45 _ 0.21 cycles/min). Data represent 2 consecutive 1-min intervals. 
When uninterrupted and without addition of any external stimuli, spontaneous 

























Chapter 5  
 






The contraction and relaxation of vascular smooth muscle is responsible 
for the maintenance of vascular tone, which is a major determinate of blood 
pressure. However, the molecular events leading to the contraction and 
relaxation of vascular smooth muscle are poorly understood.  The development 
of 3-dimensional bioengineered tissues provides an opportunity to investigate the 
molecular events controlling vascular tone in vitro.   Here, we used fibrin-gel 
casting to bioengineer functional VSM strips from primary human aortic VSM 
cells.  Our bioengineered VSM strips are functionally similar to VSM in vivo and 
remained viable in culture for up to 5 weeks.  VSM strips demonstrate 
spontaneous basal tone and can generate an active force (contraction) of up to 
85.2μN upon stimulation with phenylephrine.  Bioengineered VSM strips 
exhibited calcium-dependent contraction and calcium-independent relaxation.  




model system, which can be used to investigate the molecular events controlling 
vascular tone.    
 
 Introduction 
 Vascular smooth muscle (VSM) is a functionally critical component of 
various tissues in the cardiovascular system.  The contraction and relaxation of 
VSM that resides in the tunica media of arterioles is responsible for the 
maintenance of vascular tone, which is a major determinate of blood pressure.  
According to the American Heart Association (2007), one in three adults in the 
United States has hypertension (high blood pressure), and when untreated  can 
lead to stroke, heart attack, heart failure, or kidney failure.  Conversely, septic 
shock can result in the loss of vascular smooth muscle tone, resulting in 
hypotension.  Current strategies for controlling blood pressure in cases of both 
hypo- and hypertension include modifying vascular smooth muscle through 
cellular targets including alpha-adrenergic and calcium channel receptors.  
However, the molecular events leading to the contraction and relaxation of VSM 
are poorly understood. 
Current methods used to investigate smooth muscle contractile function 
include isolated tissue preparations, such as explanted muscle strips, which 
provide researchers with a 3-dimensional (3-D) tissue that can be easily 
subjected to controlled changes in perfusion, oxygen availability, and agonist-
induced stimulation .  An advantage of this model system is that it most closely 




composed of several different cell types that are difficult to experimentally 
manipulate individually.  Also, to prevent rapid deterioration, tissue/organ 
explants must be placed in a cold (usually 4° C) bath that does not replicate 
normal physiological conditions.  It is also difficult to control or manipulate 
expression of specific proteins in tissue explant models through transfection of 
specific cell types.   
Tissue engineering models aim to alleviate some of the problems 
encountered with current model systems being utilized.  In order to bioengineer 
functional 3-dimensional (3-D) tissue constructs, smooth muscle cells can be 
cultured within a suitable matrix.  Isolated cells can be bioengineered to yield 3-
D, homogeneous tissues, which can be maintained in culture for long periods of 
time under physiological conditions.  Bioengineered tissue can also be more 
easily manipulated for experiments by, for example, transfecting cells with 
expression vectors to control expression of an endogenous protein or to give 
expression of mutated proteins. It is also possible to reduce the number of 
experimental animals used in the future with the use of in vitro bioengineered 
models.  For these reasons, tissue engineering is a preferable approach for 
developing models with characteristics similar to those observed in vivo.   
 There have been many reports of 3-D “tissue equivalents” developed in 
vitro by culturing cells in fibrin matrices (13; 99; 126; 127).  Fibrin-based gels 
have become an effective option for engineering functional muscle tissue, 
providing a matrix that is well suited for the development of contractile tissues .  




protease thrombin, allowing the fibrin monomers to spontaneously interact and 
form fibrils. Fibrin-based gels have advantages over synthetic polymer 
approaches for tissue-equivalent fabrication.  Specifically, fibrin matrices permit 
immediate cellularity throughout the construct by cell entrapment in the forming 
gel and subsequent fibril alignment via mechanical constraint of cell-induced gel 
compaction (1).  Cell-mediated fibrin gel contraction occurs, mimicking alignment 
of muscle cells in tissue in vivo .  Within a fibrin matrix, cells rapidly migrate, 
proliferate, and digest the fibrin, replacing it with their endogenous extracellular 
matrix (ECM) (99).   
Several investigators have demonstrated the capacity to bioengineer 
primary isolated VSM cells into 3-D tissues(99; 298).  VSM cells grown in fibrin 
show increased production of ECM, collagen (208), elastic fibers (19), and also 
exhibit mechanical properties that are commensurate with vascular tissue in vivo 
(19; 99).  Furthermore, fibrin-based engineered tissues can be maintained for 
weeks in culture .  This allows investigation of the effects of cell-cell interactions, 
growth factors, mechanical and chemical stimuli, gene expression, and protein 
kinase action on tissue-level function. Although fibrin gel remodeling by VSM cells 
have been documented (99), none of these studies have reported on the active 
contractile properties (force generation) of bioengineered VSM tissues.   
 Here we used fibrin gel casting to develop a 3-D human VSM strip model 
in vitro.  Bioengineered “VSM strips” result from the spontaneous delamination of 
a confluent monolayer of primary human aortic VSM plated on a culture surface 




similar to VSM in vivo and remained viable in culture for up to 5 weeks.  VSM 
strips demonstrate spontaneous basal tone and can generate an active force 
(contraction) of up to 85.2μN upon stimulation with phenylephrine (PE).  
Bioengineered VSM strips exhibited calcium-dependent contraction and calcium-
independent relaxation.  The development of a functional bioengineered VSM 
strip provides a new in vitro model which can be used to investigate the 





Proliferative capacity of primary human aortic VSM cells.    We purchased 
primary human aortic vascular smooth muscle cells from Cambrex Inc (Cat # CC-
2571, Lot # 4F1292; Walkersville, MD), which were isolated from a 57-year-old, 
Caucasian, male donor and obtained under informed consent.  VSM growth 
media (fully supplemented with serum, growth factors, and antibiotics) was 
purchased from Cell Applications Inc (Cat # 311-500, San Diego, CA). These 
cells were positive for α-actin expression (see Cambrex Inc. product information: 
certificate of analysis), a smooth muscle-specific marker.  Primary VSM cells 
were expanded separately in 100 x 20mm culture plates. At passages 4 and 7, 
the cells were then detached from their culture flasks with 1.5 ml trypsin-EDTA, 
collected, re-suspended in growth media, and counted with a hemocytometer.  In 




incubator with media changes every other day.  At each designated time point, 
cells from 3 wells were counted, and data are presented as means ± SE.   
 
Preparation of culture plates. Culture plates (35 mm) were prepared as 
described previously [3-5, 11]. Briefly, 1.5 ml SYLGARD polydimethylsiloxane 
(PDMS) elastomer (Dow Chemical Corporation, Midland, MI, U.S.A.) was poured 
in each plate and allowed to cure for 24 h. The SYLGARD substrate provided a 
layer in which anchor materials could be easily pinned in place and provided a 
surface to which, unless coated, the cells could not adhere.  Anchor points were 
engineered on the SYLGARD surface by placing 6 mm long segments of size 0 
braided silk sutures (Ethicon, Cornelia, GA, U.S.A.) 12 mm apart in the center of 
the culture plate. The silk sutures were anchored PDMS substrate with four 
stainless steel pins (10 mm x 0.1 mm diameter) (Figure 5.1).  The culture dish 
was sterilized with 70% ethanol for 30 min. Ethanol was then aspirated, and 
culture dishes were exposed to ultraviolet light for 1 h. Each dish received 500 µl 
of growth media containing 10 U/ml of thrombin, and the dish was agitated until 
the bottom of the plate was entirely coated. Finally, 200 µl of 20 mg/ml fibrinogen 
was added to each plate and gently swirled. The fibrin polymerized 15 min later, 
and the plates were ready for cell seeding. 
 
Cell seeding and culture of VSM strips.  Primary VSM cells were expanded 
separately in 100 x 20mm culture plates. The cells were then detached from their 




and counted with a hemocytometer. Different concentrations (1x104 – 1x106) of 
VSM cells were added to the prepared culture plates in a final volume of 2.5 ml. 
Plates were placed in an incubator until the time of testing and culture media was 
changed every other day.  Time spent in culture for each construct varied 
depending on the initial seeding density.  Bioengineered tissues were grown in 
an incubator (37°C, 95% humidified air, 5% CO2).  
 
Evaluation of contractile properties.  The protocol for measuring excitability 
and contractility of engineered muscle constructs was adapted from previous 
work [3-5]. For contractility measurements of VSM strips, the culture dish 
containing the bioengineered tissue was placed on a heated aluminum platform 
that was maintained at a temperature of 37°C.    The culture media was replaced 
with 3ml of fresh growth media.  One end of the bioengineered VSM strip 
remained anchored to the culture plate and the other end was attached to a 
custom-built optical force transducer with a resolution of 1.4 µN and a range of 2 
mN.  In order to attach the bioengineered VSM strip to the force transducer, the 
pins from one end of the muscle strip were detached from the SYLGARD 
substrate.  One pin was discarded and the other pin canning was attached to the 
optical force transducer with canning wax (Figure 5.2). 
We followed standard protocols used for measuring spontaneous basal 
tone of VSM strips as follows: stretching of the tissue, followed by a period of 
equilibrium (10-20 min), where the VSM strips stabilized, resulting in the 




bioengineered VSM strips were initiated by mechanical and chemical stimuli.  
The active force was measured using the optical force transducer and force 
tracings that were digitally recorded using Lab-VIEW data acquisition software 
(National Instruments Corporation, Austin,TX, U.S.A.).  All force measurements 
were collected at 100 samples/s for 60 s, and a median filter of rank 2 was 
applied to all raw force data before being stored to minimize digitization noise 
without causing a phase delay for rapidly changing forces. Standard protocols 
were used to measure spontaneous basal tone of smooth muscle strips(275-277; 
285; 299).  Using a three-axis micromanipulator, VSM strips were stretched 
slightly and allowed to stabilize (5-10 min).  The resulting establishment of a new 
stable baseline of tension was arbitrarily set at zero to allow consistent 
measurements of active force. Contraction and relaxation in bioengineered VSM 
strips was induced by the addition of 10µM PE or 66mM potassium chloride (KCl) 
(final concentration), respectively.   Solutions of KCl and phenylepherine (PE) 
were prepared in Phosphate Buffered Saline (PBS).  All chemical were 
purchased from Sigma unless specified otherwise.   
To determine the calcium dependence of the contractile response in 
bioengineered VSM strips, parallel experiments were performed in 0 Ca2+/2mM 
ethyleneglycol-bis(β-aminoethyl)-N,N,N′,N′-tetraacetic Acid (EGTA), a Ca2+ 
chelator, in DMEM.  VSM strips were attached to the force transducer and then 
washed several times with 0 Ca2+/2mM EGTA DMEM.  Constructs were allowed 




  Mechanical stimulation of bioengineered VSM strips was induced using 
the slack test, which was developed for VSM explants (299; 300).  VSM strip 
length was rapidly decreased by 50 µm, which lowered the applied tension on the 
VSM strips enough to drop the force to zero. The response (active force) of the 
VSM strips after the decrease in tension was then recorded.   Each 
measurement was repeated seven to thirteen times, and the mean value was 
recorded.  
 
RNA Isolation.  RNA isolation was performed using the Qiagen RNeasy Mini kit 
(Qiagen Inc., Valencia, CA).  Three VSM strips from each group (1x104 or 5x105 
cells/construct) (<30g tissue) were homogenized in 600 μl of Buffer RLT using a 
hand-held, cordless homogenizer (Fisher Scientific Co., Pittsburg, PA) for 1 
minute in a 1.5 ml microcentrifuge tube.  The tissue lysate was then centrifuged 
at maximum speed for 3 minutes in a microcentrifuge to pellet cell debris.  The 
supernatant was then applied to an RNeasy mini column and subjected to 
several washes.  The total RNA was eluted with 50 μl of RNase/DNase-free 
water.   After RNA isolation, each sample was analyzed for nucleic acid purity 
using the A260/A280 ratio on a spectrophotomer.  Using the 260 nm absorbance 
value, we determined the concentration of nucleic acid within each sample.  The 
samples were then stored at -20°C until further processing. 
 
Preparation for histology.  Bioengineered VSM strips were fixed in 10% neutral 




ethanol. Bioengineered VSM strips were prepared for histology using standard 
histological techniques (tissue processing and paraffin embedding).  Sections 
were obtained using a rotary microtome and all sections were made 5–8 µm 
thick.  Sections were then stained with Harris’s hematoxylin and eosin to view 
general structure of bioengineered VSM tissues.   
 
Statistics. Tissue engineering data are presented as means ± SE for seven to 
thirteen experiments per data point. Significant differences were determined by 
ANOVA statistical analysis and the level of significance was set at P= 0.05. 




VSM strip formation.  We determined that proliferation of VSM cells was greater 
at passage 4 than passage 7 (Figure 5.3). Therefore, we used cells between 
passages 3-5 for all experiments.  VSM cells that were seeded in a fibrin gel 
where they proliferated and aligned to form a bioengineered “strip” of VSM tissue.  
Using concentrations of VSM cells between 1x104 – 1x106/construct, strip 
formation ranged from 2-35 days.  Once strip formation occurred, constructs were 
ready for functional testing.   
 
Seeding Density.  Optimal seeding density for bioengineering VSM strip formation 
was determined using active force generation as the end point measured.  We 




(Figure 5.4).  The time-to-construct formation varied depending on the initial 
seeding density, as higher seeding densities led to more rapid VSM strip 
formation.  Following VSM strip formation, constructs were attached to the force 
transducer and contractions were induced by addition of 10µM PE.   There were 
no significant differences in force between any of the seeding densities tested, 
however constructs initially seeded with 5x105 cells exhibited the greatest 
magnitude of force on average (17.65±1.7µN) (Figure 5.4).   Therefore we used 
5x105 cells per construct for all subsequent experiments.    
 
Longevity Studies.  The length of time in culture that constructs remained 
functional in response to 10µM PE was examined (Figure 5.5).  Constructs were 
tested at 1, 2, 3, and 5 weeks after cell seeding.   Constructs generated the 
greatest force at 1 and 2 weeks in culture, 41.01±4.6 and 36.71±5.1µN 
respectively.   Although no significant difference in force generation was observed 
between constructs tested at weeks 1, 2, or 3, maximal force generation of 
85.2µN was observed at one week in culture (Figure 5.5).  Constructs remained 
functional for up to 5 weeks in culture.  However force generation in response to 
PE-induced stimulation was significantly lower at the 5 week time point, 
compared to constructs tested at 1-3 weeks in culture (Figure 5.5).   
 
Mechanical and Agonist-induced Stimulation of VSM strips.  In order to assess 
the functionality of bioengineered VSM strips, contraction and relaxation was 




10µM PE displayed force generation of 41.01±4.6µN at one week in culture.  At 
all time points, the peak contractile force from PE-induced stimulation was seen 
approximately 50-60 seconds after the addition of the drug. Addition of PBS was 
used as a control and did not generate any measurable force (Figure 5.6).   
Addition of 66mM KCl to VSM strips induced relaxation (-65.8±16.9µN) 
from the basal tone.  Maximal relaxation occurred approximately 50-60 seconds 
after addition of the drug.  KCl-induced relaxation of VSM strips was consistently 
followed by sustained contraction for 4-5 minutes (Figure 5.7).   
The ability of bioengineered VSM strips to exhibit myogenic force 
generation was examined.  Mechanical-induced stimulation of VSM strips was 
accomplished by decreasing tension by a length of 50µm. Decreasing the applied 
tension on the strip caused contraction of the VSM strip, thus demonstrating a 
myogenic response (Figure 5.8).   
 
Ca 2+ sensitivity.  Constructs were pre-incubated in 0 Ca2+/2mM EGTA media and 
subsequently stimulated with 10µM PE to assess the Ca2+ dependence of the 
contractile response.  Pre-incubation of bioengineered VSM strips with 0 
Ca2+/2mM EGTA media resulted in significantly diminished force generation upon 
PE-induced stimulation, thus demonstrating the Ca2+ dependence of the 
contractile response.  In the absence of Ca2+, constructs stimulated with 10µM 
PE generated an average force of 2.6 ±1.2µN compared to 27.98 ±4.1µN of force 




 KCl-induced relaxation of VSM strips was independent of Ca2+, as VSM 
strips stimulated with 66mM KCl in 0 Ca2+/2mM EGTA media did exhibit 
relaxation (-31.0 ±3.2µN) from the basal tone.  However, in the absence of Ca2+, 
no sustained contraction was seen following KCl-induced stimulation.  Instead, 
VSM strips exhibited sustained relaxation for 4-5 minutes (Figure 5.7).  Therefore, 
KCl-induced contraction is Ca2+ dependent.   
 
RNA Content of Bioengineered VSM strips.  Total RNA was isolated from VSM 
strips with seeding densities of 1x104 and 5x105 cells/construct.  RNA was 
isolated 48 hours and 2 weeks after cell seeding.  At 48 hours, constructs seeded 
with 1x104 showed significantly lower RNA content (1.58±.27µg/ml) compared to 
constructs seeded with 5x105 cells (74.76±21.34µg/ml).  However, two weeks 
after cell seeding, there was no significant difference in RNA content between 
constructs seeded with 1x104 and 5x105, 90.78±6.66µg/ml and 68.82±5.17µg/ml 
respectively (Figure 5.10).   
 
Histology.  Bioengineered VSM strips were prepared for histology using standard 
histological techniques (formalin fixation and paraffin embedding).  Sections were 
stained with hematoxylin/eosin to view general structure of the tissue (Figure 
5.11).  Histological sections revealed portions of the bioengineered strip in which 









Previous research techniques used to investigate vascular smooth muscle 
physiology, including tissue culture, cell suspensions, and tissue explants have 
advanced our knowledge of smooth muscle function (166; 299; 301). However, 
each method has its own limitations; thus limiting our ability to understand VSM 
function.  Technological advancements in the field of tissue engineering, including 
the utilization of 3-D fibrin matrices, offered a novel opportunity to investigate 
VSM function via bioengineering 3-D VSM strips.  Bioengineered tissues 
incorporates three dimensionality resembling tissue explants, a homogenous 
population of cells similar to cell suspensions, and utilizes tissue culture 
techniques to provide a controlled environment under physiological conditions in 
which tissues can survive for extended periods of time(1; 95; 126; 133; 170; 302).  
A fibrin matrix is well suited for bioengineering contractile tissues, and fibrin-
based scaffolds have successfully been used to bioengineer gastrointestinal and 
vascular smooth muscle (1; 99).  However, no previous studies have reported on 
the active contractile properties (force generation) of VSM cells bioengineered in 
fibrin matrices.   
Using fibrin-gel casting, we have demonstrated the ability to bioengineer 
functional VSM strips from primary human aortic VSM cells.  The “strip model 
design” was previously developed to facilitate measurement of contractile 




that of native tissues (161; 303).  Utilizing a homogenous population of aortic 
VSM cells isolated from human donors eliminated the need to sacrifice 
experimental animals for these studies.  In addition, using human VSM cells are 
ideal in terms of direct relevance to human health.  We found that primary human 
VSM cell proliferation was greatly reduced at passage seven (Figure 5.3), 
therefore we used cells from passages 3-5 for all experiments.    
When human VSM cells were seeded on a fibrin gel, they self-organized, 
forming a 3-D strip of tissue.   The rate of VSM strip formation was dependent on 
the number of cells initially plated, as higher seeding densities led to more rapid 
strip formation.  Once strip formation occurred, physiologic functionality 
(contractility) was examined.   The culture dish containing the bioengineered 
tissue was placed on a 37°C heated aluminum platform and the bioengineered 
VSM strips were attached to an optical force transducer (Figure 5.2).  Although 
the rate of VSM strip formation was dependent on the number of cells initial 
plated, the initial seeding density did not appear to effect force generation.  There 
was no significant difference in the magnitude of force generated by VSM strips 
regardless of the initial seeding density (Figure 5.4), which was consistent with 
previous studies involving fibrin-based muscle constructs (1; 127).  The cells 
appeared to proliferate within the fibrin gel only until they reached confluence, 
regardless of the seeding density.  We measured total RNA content of VSM strips 
with initial seeding densities of 1x104 and 5x105 cells/construct at 48 hours and 2 
weeks (Figure 5.10).  Although constructs initially seeded with 1x104 cells had 




hours, there was no significant difference between the two seeding densities at 2 
weeks.  This suggests that density-dependent contact inhibition of cell division 
had occurred during the formation of the VSM strips.  Alternatively, the fibrin-
based scaffold may only support the metabolic activity for a limited number of 
cells.   
Bioengineered VSM strips exhibited physiological behavior functionally 
similar to VSM in vivo upon mechanical and agonist-induced stimulation.  
Mechanical stimulation of bioengineered VSM strips was induced using the slack 
test, which was developed for VSM explants (166; 300).  Briefly, VSM strip length 
was rapidly decreased enough to drop the force to zero.  As the VSM strip was 
shortened by decreasing the applied tension, force redeveloped, thus 
demonstrating a myogenic response (Figure 5.8).      
Agonist-induced stimulation showed that of bioengineered VSM strips 
were functionally similar to VSM in vivo.  Previously, Morgan and colleagues  
demonstrated that explanted VSM strips stimulated with 10µM PE exhibited a 
contractile response. Our results were consistent with Morgan’s findings, as 
bioengineered VSM strips stimulated with 10µM PE exhibited contraction (force 
generation of 41.01±4.6µN) at one week in culture.  Induced contractions were 
specific to addition of PE, as addition of PBS did not induce contraction of 
bioengineered VSM strips (Figure 5.6).  The kinetics of PE-induced contraction of 
bioengineered VSM strips resembled the kinetics of PE-induced contraction in 
VSM explants (166), and peak contractile force from PE-induced stimulation was 




Addition of 66mM KCl to VSM strips induced relaxation (-65.8±16.9µN) 
from the basal tone and maximal relaxation occurred approximately 50-60 
seconds after addition of the drug.  KCl-induced relaxation of VSM strips was 
consistently followed by sustained contraction for 4-5 minutes (Figure 5.7), which 
was also physiologically similar to VSM in vivo (166).   
Bioengineered VSM strips demonstrated the ability to contract and relax 
within seconds, similar to the capacity seen in vivo.  PE-induced contraction did 
not inhibit KCl-induced relaxation or vice versa, as bioengineered VSM strips 
demonstrated an immediate shift from contraction to relaxation or the reverse 
upon addition of the appropriate drug.  Further, agonist-induced contraction of 
bioengineered VSM strips was Ca2+-dependent, as in the absence of Ca2+ (0 
Ca2+/2mM EGTA media) addition of PE or KCl did not induce a contractile 
response (Figures 5.7 and 5.9).  However, KCl-induced relaxation of VSM strips 
was independent of Ca2+, as VSM strips stimulated with 66mM KCl in the 
absence of Ca2+  (0 Ca2+/2mM EGTA media) did exhibit relaxation (-31.0 ±3.2µN) 
from the basal tone (Figure 5.7). Therefore, bioengineered VSM strips exhibited 
several physiologically functional behaviors similar to that seen in vivo.   
These studies demonstrate the feasibility of using primary human VSM 
cells to organize into contractile 3-D contractile tissues and provide evidence of 
physiological functional bioengineered VSM tissues.  Our bioengineered VSM 
strips remained viable for at least 35 days in culture (Figure 5.5).  Further, 
bioengineered VSM strips are highly reproducible and will offer an effective 




major advantages of previously described research methods into one technique.  
This bioengineered model could be used by other investigators for various 
applications, including its utility as a tool for basic research to investigate the 
cellular/molecular mechanisms underlying contraction and relaxation of VSM.  
Incorporation of tissue engineering components with cellular/molecular based 
projects has become a powerful approach for basic research.  Thus, this 
research may contribute to a more complete understanding of the molecular 
events controlling vascular tone and could lead to the development of new 























Figure 5.1 Methodology for the formation of bioengineered VSM strip. 
Tissue culture plates were coated with PDMS and anchor points were 
engineered by pinning silk sutures 12 mm apart in the center of the culture plate 
with four stainless steel pins.   The plate was sterilized and then a thrombin/fibrin 
solution was mixed in the culture plate which led to polymerization.  Following gel 
polymerization, primary human VSM cells were plated on the surface of the fibrin 
gel.   Cell expansion and increased cell-cell contact resulted in delamination of 
the cell monolayer, which was initiated at the periphery of the culture plate and 
progressed towards the center. The delaminating cell monolayer remained 
attached to anchor points that were placed in the culture dish. Bioengineered 
VSM strips were deemed ready for functional testing when the monolayer formed 














Figure 5.2 Evaluation of Contractile Properties of VSM strips. 
Photograph B is higher magnification of photograph A.  For contractility 
measurements, the culture dish containing the bioengineered tissue was placed 
on a heated (37°C) aluminum platform.  One end of the bioengineered VSM strip 
remained anchored to the culture plate with two minuten pins (right side of 
bioengineered tissue in photographs A and B).  In order to attach the 
bioengineered VSM strip to the force transducer, the pins from one end of the 
muscle strip (left side of VSM strip in photographs) were detached from the 
SYLGARD substrate.  One pin was discarded and the other pin was attached to 
the optical force transducer (resolution of 1.4 µN and a range of 2 mN) with 
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Figure 5.3 Proliferation of VSM cells 
The proliferative capacity of primary VSM cells was evaluated at passage 4 and 
passage 7.  Each time point represents the average number of cells counted 





































Figure 5.4  Evaluation of cell seeding density on the contractile response of 
VSM 
Constructs were plated using varying cell densities suspended in a fibrin gel.  We 
utilized cell densities that ranged from 1x104 – 1x106 cells per construct.  PE-
stimulation was used to evaluate active contractile force generation.  There were 
no significant differences in force generated between any of the seeding 
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Figure 5.5 Longevity Studies. 
We evaluated the stimulated active force of VSM strips over time in culture.  All 
constructs were seeded with 500K cells/plate and force was measured at 1, 2, 3, 
and 5 weeks.  Constructs generated the greatest force at 1 and 2 weeks in 
culture, 41.01±4.6 and 36.71±5.1µN respectively.   Although constructs remained 
viable in response to PE for up to 5 weeks, force generation was significantly 








































Figure 5.6  Kinetics of VSM Strips in Response to Phenylephrine 
Upon 10µM stimulation with PE, measurements were collected at 100 
samples/second for 60 seconds using LabView Data Acquisition software.  A 
graph was generated using Microsoft Excel depicting the details of the kinetics of 
the response to PE-induced stimulation.  PBS (200µl) was added to VSM strips, 









































With Ca2+ Without Ca2+
 
Figure 5.7  Effects of KCl-induced stimulation on VSM stirps. 
Addition of 66mM KCl to constructs in growth media induced relaxation from the 
basal tone for 50-60 seconds followed by sustained contraction for approximately 
four minutes.  Addition of 66mM KCl to constructs in 0 Ca2+/2mM EGTA media 
led to sustained relaxation for approximately four minutes and no contractile 
response was seen.  Data points represent four successive readings of changes 
from the basal tone of VSM strips following KCl stimulation in growth media or 0 













































Figure 5.8  Kinetics of Myogenic Generation of Force. 
Tension of VSM strips was decreased by 50µN and measurements were 
collected at 100 samples/second for 60 seconds using LabView Data Acquisition 
software.  A graph was generated using Microsoft Excel depicting the details of 
the kinetics of the response to the decrease in tension.  VSM strips consistently 

















































Figure 5.9  Ca2+ Dependence of Phenylephrine-Induced Contractile 
Response. 
Pre-incubation of bioengineered VSM strips with 0 Ca2+/2mM EGTA media and 
stimulated with 10 µM PE resulted in significantly diminished force generation 
(2.6 ±1.2µN) compared to force generated by constructs in the presence of Ca2+ 
(27.98 ±4.1µN).  Addition of 66mM KCl induced relaxation of VSM strips from the 
basal tone in the presence and absence of Ca2+ (-65.8±16.9µN and -31.0 ±3.2µN 
respectively).   In absence of Ca2+, no sustained contraction was seen following 
KCl-induced stimulation.  Instead, VSM strips exhibited sustained relaxation for 
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Figure 5.10  Evaluation of RNA Content in VSM Strips. 
Total RNA was isolated from VSM strips with seeding densities of 1x104 and 
5x105 cells/construct at 48 hours and 2 weeks after cell seeding.  At 48 hours, 
constructs seeded with 1x104 showed significantly lower RNA content 
(1.58±.27µg/ml) compared to constructs seeded with 5x105 cells 
(74.76±21.34µg/ml).  At two weeks after cell seeding, there was no significant 
difference in RNA content between constructs seeded with 1x104 and 5x105, 
90.78±6.66µg/ml and 68.82±5.17µg/ml respectively.  Data represent means of 



























Figure 5.11  Histology of VSM strips. 
Histological cross-section of VSM strip stained with Harris’s hematoxylin and 
eosin.  Photograph (600x magnification) showing a portion of the bioengineered 
strip in which there are cells within the fibrin gel as well as undigested pieces of 




Chapter 6  
 
 Development of a Micro-Perfusion System for the Culture of Bioengineered 
 




Tissue engineering strategies are being utilized to develop functional 3D 
heart muscle in vitro.  Work within our own group has been focused on the 
development of bioengineered heart muscle (BEHM) utilizing fibrin gel as a 
support matrix.  As tissue engineering models of heart muscle are developed in 
the laboratory, a critical technological challenge remains the ability to delivery 
nutrients to the entire tissue construct.  In order to address this specific need, we 
have developed a novel perfusion system for cardiac tissue engineering 
applications.  The system consists of a custom micro-incubator, designed to 
house ten 35 mm tissue culture plate on independent platforms for controlled 
fluid delivery and aspiration.  Temperature, pH, and media flow rate and 
oxygenation are all regulated.  In the current study, we describe the compatibility 
of this micro-perfusion system with BEHMs.  We demonstrate that the perfusion 
system is capable of supporting construct viability (mitochondrial activity, total 
protein, total RNA) and maintaining contractile properties (twitch force, specific 






 Tissue Engineering is been defined as the application of principles and 
methods of engineering and life sciences toward the fundamental understanding 
of structure-function relationships in normal and pathological mammalian tissues 
and the development of biological substitutes to restore, maintain, or improve 
tissue functions (6).  Tissue engineering strategies are being utilized to develop 
functional 3D heart muscle in vitro (6).  More recent research has focused on the 
development of cell based cardiac pumps and tissue engineered ventricles (304): 
devices capable to generating intra-luminal pressure upon electrical stimulation. 
 Work within our own group has focused on developing 3D models of heart 
muscle utilizing self organization strategies (129), biodegradable hydrogels like 
fibrin(169) and polymeric scaffolds like chitosan (305).  The overall objective has 
been to compare different tissue engineering platforms to support heart muscle 
formation.  As tissue engineering models of heart muscle are developed in the 
laboratory, a critical technological challenge remains the ability to delivery 
nutrients to the entire tissue construct(306).  Neovascularization of the tissue 
engineered construct becomes necessary to support the metabolic activity of the 
cells, especially within the inner core of the tissue construct(307-312).   
 Micro-perfusion systems are being developed to satisfy the high metabolic 
requirements of bioengineered heart muscle (207; 313-316).  Micro-perfusion 
systems are generally accepted as systems capable of delivering continuous 
fluid flow to 3-dimensional tissue constructs to support metabolic activity of the 




remodeling of cells and extracellular matrices (317-319).  The critical 
technological challenges in designing micro-perfusion systems are the 
development of micro-chambers for the culture of 3D constructs, the ability to 
control the temperature, pH, oxygen saturation, relative humidity and fluid flow 
rate and monitor/record the changes in functional outcome of tissue constructs 
during long term in vitro culture.  In addition, the entire system needs to be run 
under sterile conditions with positive feedback control to change the flow 
variables to accommodate changes in construct phenotype.   
 Several perfusion systems have been described in the literature to support 
the formation and culture of 3D bioengineered heart muscle(320-322).  However, 
one of the major limitations of the current systems is the inability to exhibit a high 
degree of control on the process variables.  Current perfusion systems utilize a 
standard cell culture incubator to control the processing variables.  Although cell 
culture incubators have been valuable in support 2D monolayer systems, there 
have not been as efficient for the culture of tissue engineering constructs.  Three-
dimensional constructs have significantly higher metabolic requirements, which 
vary based on cell/tissue type and the degree of functional development of the 
3D constructs.  It is unlikely the current perfusion systems could adequately 
satisfy the multitude of functional requirements for tissue engineered constructs.   
In order to address this specific need, we have partnered with a 
commercial vendor (Radnoti Glass Inc, Monrovia, CA) to develop a novel 
perfusion system for tissue engineering applications.  The system consists of a 




independent platforms for controlled fluid delivery and aspiration.  Cell culture 
media is maintained in a temperature regulated reservoir and independently 
delivered to every tissue culture plate via a peristaltic pump with electronic flow 
regulation.  Temperature, pH, and media flow rate and oxygenation are all 
regulated.  One of the main advantages of the current system is that all 
processing variables are user defined and controlled, thereby eliminating the 
need for a cell culture incubator.  A second advantage of the current system is 
the ability to partner with a commercial vendor, thereby expediting the time 
required to commercialize this technology to ensure availability to all researchers.     
In the current study, we describe the compatibility of this micro-perfusion 
system with 3D bioengineered heart muscle, formed by culturing primary cardiac 
myocytes in the presence of a fibrin gel.  We demonstrate that the perfusion 
system is capable of supporting construct viability and maintaining contractile 
properties (twitch force, electrical pacing).  We provide additional support (cell 
viability, total protein, total RNA) to demonstrate the compatibility of the perfusion 




NIH guidelines for the care and use of laboratory animals (NIH Publication 
#85-23 Rev. 1985) have been observed.   All materials were purchased from 





Description of the Perfusion System 
The system consists of a custom micro-incubator designed to 
accommodate 10 tissue culture plates, each plate stacked vertically on an 
independent stage (Figure 6.1).  Cell culture media is maintained in a 
temperature regulated reservoir and is delivered to the tissue culture plates via a 
peristaltic pump.  Media oxygenation is accomplished by both direct bubbling of 
oxygen in the media reservoir or utilization of a membrane oxygenator.  Media is 
aspirated from each plate utilizing custom designed manifolds attached to a 
vacuum line.  The aspirated media is recycled to the media reservoir.  High 
relative humidity is maintained in the micro-incubator by delivering moist air from 
a humidification chamber.  Temperature, pH, oxygen saturation and fluid flow 
rate are monitored are controlled and recorded.   
Fluid entering the micro-incubator is divided into individual channels using 
luer lock connections thereby permitting independent flow to each tissue culture 
plate.  Fluid aspiration was accomplished via custom designed manifolds.  The 
consisted of a single harness with independent nozzles for each tissue culture 
plate.  The diameter of the nozzle is 0.22 mm and the distance between each 
nozzle is 1.3 mm.   
The micro-incubator consists of an independent stage for each of 10 
tissue culture plates (35 mm diameter) with 3 metal supports and 2 wings on 
either side to position the plates.  The lid of micro-incubator has been designed 
to accommodate ports for fluid inlet and outlet, delivery of moist air as well as 





Isolation of Primary Cardiac Cells 
Cardiac myocytes were isolated from 2-3 day old F344 rat hearts using an 
established method(323).   Hearts were cut into fine pieces and suspended in a 
dissociation solution (DS) which consisted of 0.32 mg/ml collagenase type II 
(Worthington Biochemical Corporation, Lakewood, NJ) and 0.6 mg/ml pancreatin 
dissolved in a buffer consisting of 116 mM NaCl, 20 mM HEPES, 1mM Na2HPO4, 
5.5 mM glucose, 5.4 mM KCl and 0.8 mM MgSO4.  Digestion was carried out in 
an orbital shaker for 5 minutes at 37oC, after which the supernatant was replaced 
with fresh DS and the digestion process was continued for an additional 30 
minutes.  At the end of the digestion process, the supernatant was collected in 5 
ml of horse serum (Invitrogen Corporation, Auckland, New Zealand), centrifuged 
at 1500 rpm for 5 minutes and the cell pellet was resuspended in 5 ml horse 
serum.  Fresh DS was added to the original, undigested tissue and the digestion 
process was repeated an additional 2-3 times.  Cells from all the digests were 
pooled, centrifuged and then suspended in culture medium (CM) consisting of 
320 ml M199, 100 ml F12k, 50 ml fetal bovine serum, 25 ml horse serum, 5 ml 
antibiotic-antimycotic (Invitrogen Corporation, Auckland, New Zealand), 
hydrocortisone 40 ng/ml and insulin 100 ng/ml.   
 
Fabrication of Bioengineered Heart Muscle 
The detailed method for preparing the culture surface for engineering 




modified to engineer cardiac muscle [23].  Briefly, 35 mm culture plates were 
coated with 1.5 ml of a polydimethylsiloxane (PDMS) elastomer (Dow Chemical 
Corporation, Midland, MI).  An elbow connector was attached to one end of the 
35 mm plate to accommodate fluid delivery (Figure 6.2A).  Anchor points were 6 
mm long segments of size 0 braided silk sutures (Ethicon, Cornelia, GA) pinned 
12 mm apart in the center of the culture surface (Figure 6.2B).  Five hundred 
micro-liters CM containing 10 U/ml thrombin were plated on the surface of 35 mm 
cell culture plates coated with SYLGARD (polydimethylsiloxane - PDMS, type 
184 silicone elastomer).  After this, 200 μl of 20 mg/ml fibrinogen was added to 
the 35 mm plate.  The solution was mixed to promote the formation of a fibrin gel 
within 10-15 minutes in a 37°C incubator.  Primary cardiac cells were diluted in 
CM and plated at 1 million cells in 2 ml of CM/35 mm plate after complete gel 
formation (Figure 6.2C).  Gel compaction resulted in the formation of 
bioengineered heart muscle (BEHM) approximately 6 days after initial cell plating 
(Figure 6.2D).  At the time of formation, BEHMs were positioned directly in front 
of the elbow connector (Figure 6.2E, F).  The cells were cultured in an incubator 
at 37oC and 5% CO2 with medium changes every second day.   
 
Media Delivery and Aspiration to BEHMs 
 In order to accommodate BEHMs within the micro-incubator, the 35 mm 
tissue culture plate was transferred from the cell culture incubator.  This 
eliminated any need to physically handle the BEHM thereby reducing the likely of 




independent platforms within the micro-incubator.  Fluid channels for media 
delivery and media aspiration were positioned for each plate (Figure 6.3).  Media 
delivery was accomplished by utilization of a peristaltic pump which delivered 
oxygenated media to the micro-incubator (Figure 6.3A).  Prior to entering the 
micro-incubator, fluid flow was divided into independent channels for delivery to 
each tissue culture plate utilizing multiple leur locks connectors in series.  Media 
was independently delivered to each BEHM via the elbow connector attached to 
each 35 mm tissue culture plate.  The media flow rate was set at 10 ml/min.  For 
media aspiration, we utilized a custom designed harness which consisted of a 
single manifold with independent nozzles leading to each tissue culture plate 
(Figure 6.3B).  The output of the harness was attached to vacuum for media 
aspiration.  Aspirated media was recycled to the media reservoir and re-
circulated through the perfusion system.   
  
Placement Bioengineered Heart Muscle within the Micro-Incubator  
 The micro-incubator was designed with independent stages to 
accommodate 35 mm tissue culture plates, surrounded by a water-jacketed 
reservoir for temperature regulation (Figure 6.4A).  In order to accommodate 
placement of tissue culture plates, the micro-incubator was transferred to a cell 
culture incubator.  Once the plates were securely positioned within the micro-
incubator they were sealed and returned to the perfusion system (Figure 6.4B).  
Media delivery to each plate was accomplished via an elbow connector while 





Running the Perfusion System 
In order to sterilize the system, 70% ethanol was perfused through all 
components at a flow rate of 50 ml/min for 30 minutes.  The system was than 
perfused three times with DPBS for 30 minutes each to ensure complete removal 
of the ethanol.   After sterilization and washing, cell culture media was transferred 
to the media reservoir via a fluid injection port using 60 ml syringes.  This 
mechanism of media delivery ensured that the fluid reservoir remained sealed 
thereby assuring sterility.  The media was perfused for one hour prior to 
introduction of BEHMs to ensure stabilization of system variables (temperature, 
oxygen saturation, and pH).   
After stabilization of the system variables, 35 mm cell culture plates with 
BEHMs were placed in the micro-incubator.  In order to transfer the plates, the 
micro-incubator was separated from the perfusion system and placed in a cell 
culture hood.  The plates were positioned on the independent stages and 
secured in place with the wings.  Individual ports for media delivery were 
attached to each tissue culture plate and the outflow manifold was positioned.  
The micro-incubator was sealed and returned to the perfusion system.  Once the 
culture plates were secured in the micro-incubator, it was sealed and returned to 
the perfusion system, limiting any risk of contamination.  The entire process for 
the placement of the tissue culture plates took 10-15 minutes.  During this time, 
media perfusion was continued, however, completely bypassing the micro-




Once the BEHMs were secured positioned in the micro-incubator, media 
flow to the 35 mm tissue culture plates was initiated.  BEHMs were maintained in 
the perfusion system for one hour.  After the one hour run, the BEHMs were 
recovered and assessed for contractile activity, cell viability, total protein and 
total RNA and expression of myosin heavy chain α/β, SERCA2 and 
phospholamban.  As controls, we utilized BEHMs that were maintained in a 
standard cell culture incubator for the same duration of time.  The controls were 
maintained in 35 mm tissue culture plates which were modified to accommodate 
perfusion.   
 
Sterility Test 
The cell culture media was tested for contamination after every perfusion 
run by recovering spend media at the end of the run and culturing in a cell culture 
incubator for 7 days.  The media was microscopically evaluated for any 




To examine the cell viability of BEHMs cultured in the perfusion system as 
well as under standard culture conditions, we used a WST-1 Assay protocol 
(Roche Applied Science, Indianapolis, IN).  Briefly, 100μl of WST-1 solution was 
added to culture dishes containing BEHMS and 2ml of fresh media.  After an 




and compared to a standard curve.  The incubation time was optimized in prior 
pilot studies.  Three plates were utilized for the perfusion run and three plates as 
controls.  A total of 3 absorbance readings were acquired for each plate.     
 
Evaluation of Contractility 
The method for evaluating the contractility of tissue engineered constructs 
has been described in detail(126; 170).  Briefly, the BEHM was placed in CM at 
37oC between parallel platinum electrodes.  One end was fixed to the plate and 
the other end was attached to a custom-built optical force transducer.  Stimulated 
active force (response to a single electrical impulse) measurements were then 
recorded at 5 volts, with a frequency of 1 Hz and a 10 ms pulse width.  The 
length of each BEHM was adjusted to obtain maximum stimulated active force 
using a multi-axis micromanipulator.  This optimal length was designated as Lo 
and was recorded.  The cross-sectional area of the BEHMs was calculated from 
the construct diameter which was determined by a calibrated eyepiece reticle 
with a resolution of 5 µm.   The construct was assumed to be cylindrical for this 
calculation.  The specific force (kN/m2) of each BEHM was determined by 
normalizing the stimulated twitch force to the total cross-sectional area.  The 
BEHM was electrically paced at frequencies between 1 and 5 Hz, with all other 
stimulation parameters remaining constant.  The contractile properties of 10 







 A total of 6 plates were analyzed for the total protein content, 3 after a 1-
hour perfusion system culturing and 3 after standard culturing conditions.  To 
extract total protein from each plate, we used M-PER® Mammalian Protein 
Extraction Reagent (Pierce, Rockford, IL) supplemented with HaltTM Protease 
Inhibitor Cocktail Kit (Pierce, Rockford, IL), following the manufacturer’s 
instructions.   The media in all tissue culture plates was aspirated and plates 
were washed with DPBS.  Briefly, the HaltTM Protease Inhibitor Cocktail and 
supplied EDTA Solution was added at 10 μl/ml to the M-PER® Mammalian 
Protein Extraction Reagent.  Next, 400 μl of the solution was added to each 
culture dish and allowed to gently rock for 10 minutes.  Each lysate was then 
collected separately and centrifuged down for 10 minutes at 14,000 x g.  The 
supernatant was collected and analyzed for protein concentration using Bio-Rad 
Protein Assay Dye Reagent Concentrate (Bio-Rad, Hercules, CA).  
 
RNA Isolation 
 RNA isolation was performed using the Qiagen RNeasy Mini kit (Qiagen 
Inc., Valencia, CA).  Briefly, the cell monolayers were disrupted with the addition 
of 350μl of Buffer RLT (RNeasy Lysis Buffer), collected into a microcentrifuge 
tube, homogenized using a hand-held rotor homogenizer, and centrifuged at 300 
x g for 5 minutes.  The supernatant was discarded and 70% ethanol was added 




to various washes, according to manufacturer’s protocol.  The total RNA was 
eluted with 30μl of RNase/DNase-free water.   
After RNA isolation, each sample was analyzed for nucleic acid purity and 
concentration of nucleic acid using the A260 and A260/A280 ratio on a 
spectrophotomer.  The samples were then stored at -20°C until further 
processing. 
A total of 6 tissue culture plates were utilized for RNA extraction, with 3 
plates each for perfusion and controls.  Every plate was treated independently.   
 
Statistical Analysis 
We used one way ANOVAs combined with the Tukey’s test for all pair-
wise comparisons.  Minitab V13.31 (State College, PA) was used for statistical 




Usability of the Perfusion System 
 The perfusion system consisted of several components, some of which 
were custom fabricated for this specific application.  Initial prototyping, assembly 
and validation required a significant investment of time.  Multiple configurations 
were often evaluated and repeated prototyping was required.  Placement of the 
sensors required the design of custom holders, configured to accommodate the 




regulation.  However, after initial design, prototyping and validation, the system 
was fairly easy to use.  Individual components (except the micro-incubator) were 
not separated from the system; sterilization, washing and transfer of media were 
all possible without physical removal of any component. 
 
Fabrication of BEHMs 
 Our methodology for the fabrication of BEHMs has been previously 
described (reference).  In order to accommodate placement in the micro-
incubator, the tissue culture plates had to be fitted with an elbow connector at 
one end; the lids did not completely cover the plates as a result.  However, there 
were no signs of media contamination resulting from this.  The entire process of 
BEHM formation was fully reproducible.  Spontaneous contractions of the 
primary cardiac myocytes were visible within 24 hours after plating.  A cohesive 
cell monolayer was seen to be contracting in synchrony with 48 hours after 
plating and BEHM formation was complete within 6 days after initial cell plating.    
 
Placement of BEHMs within Micro-Incubator 
 In order to transfer the BEHMs to the perfusion system, the micro-
incubator was placed within a cell culture hood.  The 35 mm tissue culture plates 
in which the BEHMs had formed were then placed on individual stages within the 
micro-incubator.  Channels for fluid delivery and aspiration were then positioned.  
During this process, there was no physical handling of the BEHMs as the entire 




physical damage to any constructs during the physical transfer to the micro-
incubator.  Since transfer of the BEHMs to the micro-incubator occurred within a 
cell culture incubator, there were no signs of media contamination during 
perfusion.  This was validated by culturing spent media in a cell culture hood for 
7 days.   
 
Stabilization of System Variables 
 Temperature was regulated throughout the perfusion system by circulating 
hot water from a thermo-circulator through the water-jackets of all perfusion 
components.  Maintaining a temperature of 38.1oC in the thermo-circulator was 
sufficient to maintain a media temperature of 37.4oC.  Temperature stabilization 
required approximately 30 minutes.  Media pH was maintained by adding HEPES 
buffer at a concentration of 25 mM and the pH was maintained at 7.4 for the 
duration of the perfusion run.  In addition to regulating temperature and pH, the 
oxygen saturation of the media was maintained utilizing a membrane oxygenator.  
Temperature and pH values were digitally recorded while oxygen saturation was 
not.   
 
Media Delivery and Aspiration 
 In order to accomplish media delivery to the BEHMs within the micro-
incubator, the flow was divided into independent channels prior to entering the 
micro-incubator.  This ensured independent media delivery to each BEHM.  




harness leading out of the micro-incubator.  Although multiple configurations 
were evaluated for media delivery and aspiration (e.g. individual ports for media 
aspiration), we found this configuration to be most suitable, based on the amount 
of tubing required, the overall usability and the ability to achieve uniform fluid 
delivery/aspiration.  Media flow was perpendicular to the BEHMs.  However, this 
did not result in any physical damage to the BEHMs resulting from fluid stress.  
There were no incidences of physical damage to the BEHMs resulting from 
media flow in the micro-incubator.   
 
Ability of BEHM to Tolerance Fluid Flow 
 Upon recovery of the BEHM after perfusion, we visually evaluated the 
overall integrity of the constructs.  There were no signs of separation of the tissue 
mass from the sutures or any signs of physical movement of the sutures.  We did 
not observe any breakage of the BEHM at any point along the tissue construct.  
Under microscopic evaluation, we observed spontaneous contractions of the 
BEHMs after perfusion.  The frequency of the spontaneous contractions was in 
the range of 1-2 Hz, similar to the controls.  Overall, the BEHMs were able to 
tolerate the fluid flow very well with no visible signs of physical damage to the 








 The cell viability, evaluated utilizing the WST assay (which measures 
mitochondrial activity) was maintained during BEHM perfusion.  The average 
absorbance at 580 nm was found to be 0.863 ± 0.056 for control BEHMs and 
0.840 ± 0.040 for BEHMs after perfusion (Figure 6.5).  We utilized N=3 for both 
groups.  There was no significant difference between the absorbance values of 
the BEHMs after perfusion, therefore validating construct viability. 
 The total protein of control BEHMs was found to be 472.9 ± 19.3 
µg/BEHM and 387.3 ± 37.9 µg/BEHM for constructs after perfusion (Figure 6.6A).  
The total RNA content of control BEHMs was found to be 3.84 ± 1.73 µg/BEHM 
and 3.25 ± 0.20 µg/BEHM for constructs after perfusion (Figure 6.6B).  N=3 for 
both groups and there was no significant difference between the total protein and 
total RNA between control BEHMs and BEHMs after perfusion.   
 
Diameter and Cross-sectional Area of BEHMs after Perfusion 
 We evaluated the diameter, cross-sectional area, twitch force, specific 
force (twitch force normalized to total cross-sectional area, and pacing 
characteristics of the BEHMs.  As an initial indicator of contractile function, the 
BEHMs were subjected to single electrical impulses and found to generate twitch 
force (Figure 6.7).  The magnitude of the twitch force for the BEHMs after 
perfusion was comparable to the twitch force of control BEHMs (Figure 6.7).  By 
evaluating individual force tracings, we also found that the rate of contraction and 




 The average diameter of the control BEHMs was found to be 992.9 ± 69.8 
µm and 797.2 ± 46.7 µm (Figure 6.8A).  The cross-sectional area of the BEHMs 
after perfusion was calculated to be 79.0 ± 11.8 x 105 µm2 and 50.6 ± 6.0 x 105 
µm2 for control BEHMs (Figure 6.8B).  We utilized N=5 for both groups.  There 
was a statistically significant difference between the diameters and the cross-
sectional of the BEHMs after perfusion with p=0.048 for the diameters and 
p=0.038 for the cross-sectional area.     
  
Twitch Force and Specific Force of BEHMs after Perfusion 
The average twitch force for control BEHMs was found to be 444.3 ± 
133.85 µN and 426.1 ± 50.96 µN for BEHMs after perfusion (Figure 6.8C).  N=5 
for each group with p=0.90.  There was no significant variation in the twitch force 
of the BEHMs after perfusion, when compared to control BEHMs.  The degree of 
variability of the twitch force for control BEHMs was considerable greater than 
that of BEHMs after perfusion.     
 The average specific force of the control BEHMs was calculated to be 
0.60 ± 0.17 kN/m2 and 0.89 ± 0.14 kN/m2 for BEHMs after perfusion.  We utilized 
N=5 for the specific force.  There was no statistical difference between the 
specific force between the two groups, with N=5.  Although the difference in 
specific force was not statistically significant, evaluating the actual numbers for 
both groups provides useful insight.  The specific force for the control BEHMs 
were calculated to be 0.52, 0.68, 0.38, 0.19, 1.2 kN/m2.  The specific force for the 





Electrical Pacing of BEHMs 
 We evaluated the ability of the BEHMs to be electrically paced at 
frequencies of 1-4 Hz (Figure 6.9).  At all the pacing frequencies we tested, the 
BEHMs were able to elicit repetitive contractions that correlated directly with the 
number of electrical impulses.  In addition, the BEHMs were able to relax to 
baseline conditions between successive contractions, even at the higher pacing 
frequencies.  The ability of the BEHMs to respond to electrical pacing after 




 Our previous work has focused on the development of tissue engineering 
platforms to support the formation of functional 3-dimensional heart muscle in 
vitro.  We have evaluated the feasibility of utilizing self organization strategies, 
biodegradable hydrogels and polymeric scaffolds for cardiac tissue engineering 
applications.  Technological advancements have permitted the formation of 
tissue constructs which exhibit a high degree of phenotypic resemblance to 
normal mammalian heart muscle.  As tissue engineering models are developed, 
it becomes necessary to define physiological culture conditions in vitro which 
more closely resemble in vivo conditions.  This often includes mechanical stretch, 
chemical stimulation with growth factors and the micro-perfusion systems.  The 




perfusion system that has been developed in our laboratory to support the culture 
of 3-dimensional tissue constructs.   
 The central element of the perfusion system is a micro-incubator, custom 
designed to accommodate culture of 35 mm tissue culture plates.  Independent 
platforms have been fabricated to allow spatial distribution of the tissue culture 
plates.  The micro-incubator is the only component of the perfusion system which 
needs to be removed to accommodate the placement of the plates.  This 
accommodates ease of operation of the system.  Physical transfer of BEHMs to 
the micro-incubator is accommodated by transferring the entire 35 mm tissue 
culture plate from the cell culture incubator to the micro-incubator.  The transfer 
takes place under sterile conditions in a cell culture hood, which minimizes any 
risk of contamination to the BEHM.  Therefore, with the current configuration, we 
were able to ensure physical transfer of the BEHMs to the perfusion system 
without any physical handling of the constructs thereby reducing damage and 
contamination.    
In order to accommodate compatibility of BEHMs with the micro-incubator, 
we need to modify the tissue culture plates by attachment of an elbow connector 
to one end.  Though a simple modification, our concern was the introduction of 
contamination, as the lids of the tissue culture plates were not completely 
covering the plates (due to the elbow connector).  This was, however, not a 
problem.  In the process of this study, we have fabrication over 50 BEHMs with 




We configured independent flow channels to accommodate media delivery 
to each tissue culture plate.  Cell culture media was maintained in a water 
jacketed reservoir and delivered to the micro-incubator in a single channel.  Prior 
to entering the micro-incubator, the fluid flow was divided into multiple outflows 
utilizing leur lock connectors in series.  Although this arrangement required a 
significantly large amount of tubing, media easily delivered to each tissue culture 
plate.  In our configuration, fluid flow was perpendicular to the orientation of 
BEHMs.  Although it is likely that fluid stresses would have a significant impact 
on 3-dimensional tissue remodeling and that parallel versus perpendicular flow 
regimes would result in very different physiological outcomes, this factor was not 
incorporated into our current experimental design.  Rather, this would need to be 
a focus of follow up studies.  In order to accommodate media aspiration, we 
utilized custom fabricated manifolds.  Our design was based on glass Pasteur 
pipettes routinely utilized in cell culture applications.  The manifold consisted of 
multiple nozzles attached to a single harness, analogous to having multiple 
Pasteur pipettes in series.  This system proved simple and effective for media 
aspiration.  An alternative configuration for media aspiration would have been 
independent fluid channels, replicating the configuration utilized for media 
delivery.  The only limiting factor in this alternative configuration was the 
excessive amount of tubing required, making is difficult to work with.  This was 
the motivation for fabricating the manifolds, which accomplished the same task, 




 Overall, the perfusion system was easily to utilize and very compatible 
with BEHMs.  Fabrication of BEHMs, physical transfer to the micro-incubator and 
establishment of flow regimes were accomplished without any difficulty.    
 After validating the compatibility of the perfusion system with BEHMs, our 
next objective was to support culture of BEHMs within the micro-incubator.  We 
selected a one hour time point to determine the functional performance of 
BEHMs in response to media perfusion.  We found that there was no detachment 
of the BEHMs from the sutures and there were no visible signs of physical 
damage of the constructs in response to perfusion.  Spontaneous contractions of 
the BEHMs were visible under examination utilizing an inverted microscope.  
These initial metrics severed well to demonstrate physical compatibility of the 
BEHM with the perfusion system.  This is often a challenge as 3-dimensional 
tissue constructs (like BEHMs) are at any early state of development and 
vulnerable to physical damage in response to any external stimuli.  This is even 
more important when working with custom components (like the micro-incubator) 
which have not been tested in to support the culture of tissue constructs.      
 In order to evaluate the functional outcome of BEHMs in response to 
perfusion, we evaluated cell viability, total protein and total RNA.  All three 
metrics showed that the BEHMs retained functionality after being subjected to 
perfusion.   
The contractile properties of the BEHMs were also evaluated.  
Interestingly, while we found that there was no significant difference between the 




force.  Though the increase in specific force was not statistically significant, 
possibly due to the small utilized in this study combined with the variability in the 
twitch force, there was a general trend showing this increase.  Correspondingly, 
we observed a significant decrease in the diameter and total cross-sectional area 
of BEHMs in response to perfusion; this difference was even statistically 
significant.   
The increase in specific force was therefore a result of a decrease in 
diameter of the BEHMs, rather than an increase in twitch force.  Though 
speculative, this decrease in diameter could be due to decreased water retention 
of BEHMs.  The BEHMs were fairly large at the time of perfusion, in excess of 
700 µm, due to the presence of a large amount of fibrin gel.  Fibrin gel degrades 
within 2 weeks after BEHM formation resulting in a diameter of 200-300 µm.  
Hydrogels, like fibrin, have high water retention.  It is likely that fluid stress 
resulted in a decrease in water content of the BEHMs thereby resulting in 
decease in diameter and a subsequent increase in specific force.  Though non 
physiological, the change in geometry of BEHMs in response to perfusion would 
be an interesting phenomena to evaluate.  Does it indeed impact the 
physiological of the 3-dimensional tissue construct and can this be manipulated 
to enhance functional performance in response to controlled perfusion variables?   
 Our final performance metric was the ability of the BEHMs to respond to 
electrical pacing.  We found that there was no change in the pacing 
characteristics of the BEHMs after perfusion, indicative of physiological calcium 




 Collectively, the performance metrics demonstrated that BEHMs were 
able to sustain culture in the micro-incubator.  Additional metrics, histological and 
biological, would be necessary to further validate the compatibility of BEHMs with 
the perfusion system.  Follow up studies would be required to evaluate the effect 
of perfusion variables (e.g. media flow rate) on the functional performance of 
BEHMs.  The ability to support long term culture of BEHMs would also be an 
important variable.   However, the current study does provide the necessary 
framework to evaluate the effect of controlled perfusion variables on the 

























Figure 6.1  Schematic of Perfusion System 
A compact design Water Jacketed for precise temperature control the bio-
chamber incorporating a series of 10 shelves with wings that allow for easy 
placement and removal of standard 35mm disposable sample dishes.  Two 
specialized manifolds were precision fabricated to allow simultaneous placement 
of the fluid flow ports to each chamber.  In the initial design a single peristaltic 
pump drives the inflow, drawing from a water jacketed temperature controlled 
reservoir. A single vacuum line drives the outflow.  Outflow is collected in a 
vacuum flask and recycled through the system. The inflow and out flow fluid 
manifolds are configured with inline measurement of O2, pH and temperature.  
Threaded luer-lock ports at the top of the chamber in conjunction with single 
direction check valves allow for gas in flow and out flow without the possibility of 










Figure 6.2  Methodology for BEHM Fabrication 
(A) Preparation of the Tissue Culture Plates – 35 mm plates were coated with 
PDMS and then with fibrin.  An oxygen probe was positioned in the center of the 
plate.  (B)  Placement of Pins and Sutures – size 0 silk sutures were placed in 
the center of the tissue plated and positioned with 0.1 mm diameter minuten pins.  
(C)  Gel Compaction – primary cardiac cells were isolated from 2-3 day old 
neonatal rat hearts and plated on the surface of the fibrin gel (1x106 cells/plate).  
Within 2 days of cell plating, the cardiac cells promote the compaction of the 
fibrin gel.  (D)  BEHM Formation – Gel compaction continues, promoting BEHM 
formation.  (E) Orientation of the elbow connector relative to the BEHM, as seen 
from a top view.  (F)  Orientation of the elbow connector relative to the BEHM, as 











Figure 6.3  Media Delivery and Aspiration 
(A) Schematic for Media Delivery and Aspiration to BEHMs - Independent fluid 
flow was delivered to every tissue culture plate while a single harness was 
utilized for fluid aspiration.  Fluid flow was perpendicular to the BEHMs.  (B) 
Actual Configuration – Image shows a single BEHMs (B) placed within a 35 mm 
tissue culture plate with an elbow connector for media delivery (Min) and 
independent nozzles attached to a single outflow manifold for media aspiration 







Figure 6.4  Placement of BEHMs within Micro-Incubator 
 (A) Micro-Incubator - The micro-incubator consisted of independent stages for 
placement of 35 mm tissue culture plates surrounded by a water jacket for 
temperature regulation.  (B)  Placement of Plates within Micro-Incubator - Tissue 
culture plates containing BEHMs were easily transferred to the micro-incubator, 
without the need to physically handle the constructs.  (C) Configuration of 
Individual Plates – Media was delivered via an elbow connector while media 











Figure 6.5  BEHM Viability 
The cell viability was evaluated using the WST assay.  The normalized 
mitochondrial activity for the controls was found to be 0.863 ± 0.056 and 0.840 ± 
0.041 for BEHMs after perfusion.  N=6 for each group and error bars represent  
standard error of mean.  There was no statistical difference between the 2 
groups using one-way ANOVAs.   














Figure 6.6 Total Protein and Total RNA 
(A) Total Protein – the average protein for control BEHMs was found to be 472.9 
± 19.3 µg and 387.3 ± 37.9 µg for BEHMs after perfusion.  (B) The total RNA 
content of control BEHMs was found to be 3.84 ± 1.73 µg and 3.25 ± 0.20 µg for 
BEHMs after perfusion.  N=3 for both groups and the numbers refer to total 
protein and/or total RNA per BEHM.  Error bars represent standard error of 
mean.  There was no statistical difference between the 2 groups for total protein 






Figure 6.7  Representative Tracings of Twitch Force 
BEHMs were electrical stimulated with a single impulse of magnitude 10 V, 
frequency 1 Hz and a pulse width of 10 ms.  The twitch force was recorded using 
an optical force transducer.  Representative tracings for control BEHMs and 

















Figure 6.8  Contractile Properties of BEHMs 
(A) Diameter – The average diameter of the control BEHMs was measured to be 
992.92 ± 69.83 µm and 792.22 ± 46.70 µm for BEHMs after perfusion.  (B) 
Cross-sectional area – The average cross-sectional area of BEHMs was 
calcuated to be 78.97 ± 11.75 x105 and 50.61 ± 6.03 x105 for the BEHMs after 
perfusion.  (C)  The average twitch force of control BEHMs was measured to be 
444.3 ± 133.9 µN and 426.1 ± 51.0 µN for BEHMs after perfusion.  (D)  The 
specific force of the BEHMs was calculated to be 0.58 ± 0.18 kN/m2 and 0.89 ± 
0.14 for BEHMs after perfusion.  For all groups, N=6 and error bars represent 
standard error of mean.  P=0.048 for (A) and 0.038 for (B).  There was no 
statistical difference between the twitch force and the specific force between the 













Figure 6.9  Electrical Pacing of BEHMs after Perfusion 
BEHMs were electrically paced at varying frequencies utilizing a 10 V impulse 





















The work described in this thesis is divided into three broad areas; 
overview of cardiovascular tissue engineering, development of functional 3-
dimensional models of smooth muscle, and micro-perfusion for bioengineered 
cardiac muscle.  Collectively, the work described in this thesis bridges the 
scientific and technological gap in several aspects of functional tissue 
engineering.    
 
OVERVIEW OF CARDIOVASCULAR TISSUE ENGINEERING 
In the first part of the thesis, a critical overview of the field of cardio-
vascular tissue engineering is provided.  Current status of the field is provided 
with an emphasis on cell sourcing, biomaterial fabrication, bioengineered models 
of cardiac and vascular tissue, and bioreactors/micro-perfusion systems.  In 
addition to providing a snapshot of the field, technological challenges which need 
to be addressed for the development clinical usable of cardio-vascular tissue 
have been provided.   
The last decade has seen the development of several models of 




demonstrates the feasibility of culturing primary cells derived from cardio-
vascular sources within 3-dimensional matrices to form functional tissue 
engineered models.  Several critical technological challenges remain, particularly 
in the fabrication of contractile models of vascular tissue and the development of 
novel micro-perfusion systems to support the long term culture of tissue 
engineered constructs.  The work described in this thesis addresses both of 
these challenges.   
 
BIOENGINEERED MODELS OF SMOOTH MUSCLE 
The second part of this thesis is focused on the development of 
bioengineered models of smooth muscle cells, both from gastrointestinal (GI) and 
vascular tissue.  The field of GI physiology has relied on the utilization of 
traditional models like 2-dimensional monolayer for basic research, with limited 
access to the advantages of 3-dimensional tissue systems.  In order to bridge 
this knowledge gap, novel bioengineered models for the anal sphincter and colon 
were developed.  To date, the models described in this thesis are the only 
published in vitro bioengineered models for GI structures.  This provides 
researchers with a powerful new tool to study GI physiology in isolated 3-
dimensional tissue constructs; something which was simply not possible before.     
 To further expand the work in smooth muscle tissue engineering, the field 
of vascular tissue was evaluated.  Although 3-dimensional tissue models had 
been developed for vascular applications, there was no data available on the 




characterization was substituted for the lack of contractile data.  It is a well known 
fact that the primary function of vascular tissue is to regulate the flow of blood 
flow through vascular tone.  Therefore, in order to address this critical knowledge 
gap, the work described on GI tissue engineering was extended into the vascular 
arena.  The primary objective was to use the experience gained with GI smooth 
muscle cells to develop a 3-dimensional model for vascular tissue engineering, 
with the primary objective of characterizing the contractile properties.   
In order to develop a model for vascular tissue engineering, human aorta 
smooth muscle cells were cultured in a fibrin matrix.  The contractile properties of 
the resulting vascular tissue constructs were characterized.  We determined that 
the vascular constructs exhibited spontaneous tone, were responsive to both 
mechanical and chemical-induced stimulation.  
The work presented in this thesis provides insight into the contractile 
behavior of bioengineered vascular constructs.  Combined with the published 
data on the biochemical properties, this represents a more complete 
characterization of bioengineered vascular constructs, thereby providing 
researchers with an expanded knowledge base. 
 
MICRO-PERFUSION FOR BIOENGINEERED HEART MUSCLE  
In the third and final part of this thesis, a novel micro-perfusion system is 
described and shown to support the culture of bioengineered cardiac constructs.  
Three dimensional tissue constructs have higher metabolic requirements 




increase in mass and cellular density of bioengineered constructs.  There are 
currently no commercially available perfusion systems for tissue engineering 
applications.  Therefore, we sought to design, fabricate and test our own 
perfusion system. 
Our system consists of a novel micro-incubator with independent stages 
for tissue constructs.  Media flow and aspiration are independently regulated for 
each plate and system variables (temperature, pH and oxygen saturation) are 
controlled.  The entire perfusion system can be maintained without the need for a 
standard cell culture incubator. This increases user control over processing 
variables, providing an opportunity to modulate culture conditions to match the 
metabolic requirements of the tissue constructs.   
Utilizing this system, we have demonstrated the feasibility of support the 
culture of bioengineered cardiac constructs for up to 24 hours.  We have shown 
that the cardiac constructs maintain twitch force, spontaneous and electrically 
induced pacing, with an increase in cell viability and expression of cardiac 
specific genes.  In addition, we have partnered with a company (Radnoti Glass 
Technology, Inc, Monrovia, CA) with an interest in commercializing this 
technology.  This will allow researchers to have access to standardized systems 








FORCE GENERATION OF BIOENIGNEERED TISSUES 
 The specific force generated by bioengineered tissues compared to whole 









Specific Force (kN/µm2) 
of in vivo Tissue 
Rabbit Sphincter 
Ring Model 
2.8 10.2                     
(human smooth muscle 
explant) 
Human Aortic 
Smooth Muscle Strip 
Model 
0.66 26  
(ferret aortic smooth 
muscle explant) 
Rat Cardiac Muscle 
Strip Model 
0.98  44.4  
(rat papillary muscle 
explant) 
 
Table 7.1 Force Generation of Bioengineered Tissues 
 
Specific force calculated for bioengineered tissues were lower than the available 
explant comparisons.  However, some of the only available comparisons of 
specific force were in different model organisms.  The lower force generated by 
bioengineered tissues could be in part attributed to the different model systems 
being compared (human muscle versus rabbit muscle), as there may be variation 
in the mechanical strength among different species.  The difference in specific 
force generated in bioengineered tissues versus explants may also be the result 
of the developmental state of the cells, since our system has not yet incorporated 
all of the environmental cues necessary for bioengineered muscle to reach full 
maturation. Furthermore, bioengineered tissues were made using a homogenous 




Although specific force of bioengineered tissues was lower than muscle 
explant comparisons, all bioengineered tissues exhibited striking tissue-specific 
functionality.  For example, the frequency of bioengineered colonic phasic 
contractions (2.45 ± 0.21 cycles/min) was similar in frequency to that seen in 
colonic muscle strips (2–4 cycles/min). The bioengineered tissues described here 
represent an early, proof-of-concept demonstration of the feasibility of 
bioengineering functional muscle tissue in vitro.  Future advances in meeting the 
various technical challenges, including the continued development of bioreactors 
and micro-perfusion systems to introduce all of the electrical, chemical, and 
mechanical stimulation required for tissue maturation, will surely lead to 




The work described in this thesis forms the foundation of a significant 
amount of ongoing research at the Artificial Heart Laboratory at the University of 
Michigan in Ann Arbor.  The research on vascular tissue engineering has 
generated significant interest within the group and has led to an initiative to 
fabricate functional models of vascular grafts.  The cell culture techniques, 
fabrication of 3-dimensional models and evaluation of contractile properties for 
the vascular graft project are all derived from the work described in this thesis.   
The work described on perfusion has generated a significant amount of 




the Artificial Heart Laboratory are utilizing the perfusion system to define 
conditions for the long term culture of bioengineered heart muscle.  The effect of 
oxygen saturation, fluid flow rate, and fluid shear stress are currently being 
evaluated.  In addition, an aggressive effort to develop the commercial potential 
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